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Abstract
Pulmonary arterial hypertension (PAH) is a rare, chronic disease with no cure. Patients with this
disease have high mortality and morbidity, experience frequent hospitalizations, readmissions,
and psychosocial burdens, and require a high degree of self-care management skills (Doyle-Cox
et al., 2016; Lattimer et al., 2016; McDevitt & Walter, 2019). More than half of PAH patients are
hospitalized within the first year following diagnosis, and about 20% are readmitted to the
hospital within thirty days of discharge (Bhattacharya et al., 2019: Tonelli, 2020). These patients
also have a high symptom burden, and these symptoms significantly affect their physical and
mental quality of life (Matura et al., 2016). As the disease progresses, so do the symptoms,
leading to an increased need for symptom monitoring and management by the patient and the
healthcare team.
The Pulmonary Arterial Hypertension Center of Comprehensive Care is an accredited facility
that serves approximately 400 PAH patients residing in the gulf south region. Evidence supports
a multidisciplinary, multi-pronged, comprehensive care model approach to PAH patients' care as
they transition through various settings.
This quality improvement project introduces two telehealth interventions to address the critical
care needs of this population. The first intervention was a provider-led postdischarge follow-up
virtual visit that occurred one week after hospitalization. The second was scheduled nurse-led
telephone calls beginning after hospital discharge. These interventions were designed to reduce
hospital readmissions for this population, encourage self-care management, and remove barriers
to quality healthcare by combining technology with best practice healthcare.
Keywords: pulmonary hypertension, pulmonary arterial hypertension, telemedicine, hospital
readmission, virtual visit, chronic disease, self-care management, transitions of care
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Implementation of a Postdischarge Virtual Visit and Nurse Follow-up Protocol to Decrease
30-Day Readmission Rates for Patients with Pulmonary Arterial Hypertension
The purpose of this project was to design a DNP quality improvement to decrease 30-day
readmission rates of patients with World Health Organization (WHO) 1 Pulmonary Arterial
Hypertension (PAH or PH). This paper describes the patient population and their disease-specific
treatments and challenges along the health-illness continuum and offers solutions to some of
those challenges. One solution was to implement a one-week post-hospital discharge follow-up
virtual visit and scheduled nurse-led telephone calls by the pulmonary hypertension nurse
coordinator.
The hospital discharge to include the patient's movement from one setting to the next is
called a "transition of care." Transitions of care can be a particularly vulnerable time for patients
that can increase the chance of adverse events like hospital readmission within 30-days of
discharge (AHRQ, 2018). Studies show that a multi-intervention approach to transitions of care
for chronic conditions facilitates safe, efficient movement between settings (Albert et al., 2015;
Health Quality Ontario, 2017; McDevitt & Walter, 2019). Early post-hospital discharge followup and nurse-led telephone follow-up are two such interventions.
Background and Significance
Pulmonary hypertension (PH) is high blood pressure in the vessels and arteries of the
lungs. It is a disease that affects both the heart and the lungs and is progressive, chronic, fatal,
and with no cure (Lau et al., 2017). The World Health Organization (WHO) developed five
groups based on the presentation of the underlying cause of PH, similar clinical presentation,
diagnostic testing, and pathophysiology to assist providers in targeted therapy and management
(Galiè et al., 2016).
This project's population focus is patients with WHO group 1 pulmonary hypertension,
which affects the small arteries explicitly in the lungs and is called Pulmonary Arterial
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Hypertension (PAH). The underlying cause for patients classified as WHO group 1 may be
idiopathic, hereditary, drug, and toxin-related or associated with other disorders. (Galiè et al.,
2016).
Epidemiology
Pulmonary arterial hypertension is a rare disease with fewer than 200,000 identified cases
in the United States (Groft et al., (2019). Researchers have conducted several global registries;
however, due to PH's etiological variability and the gaps in research for rare diseases, the
information is not robust. The most current epidemiological data estimates an incidence of about
2 to 7.6 adult cases per million and a variable prevalence of 11 to 26 million adult cases each
year (Thenappan et al., 2018). PAH affects all ages, races, and genders, though there is a female
to male ratio of 4:1 (Thenappan et al., 2018). Over the last two decades, the age at diagnosis has
increased from approximately 35 years to an average age of 52 years, and 64% of patients
diagnosed with PAH were over 65 (Lau et al., 2017).
Pathophysiology of Pulmonary Arterial Hypertension
The causes and patient demographics of PAH may vary, but the disease's symptoms and
progression are similar. In PAH, blood flow meets resistance in the narrowed pulmonary arteries
causing it to back up into the heart. This results in right heart strain, decreased cardiac output,
and heart failure (Lau et al., 2017). Right heart failure is a common cause of death in patients
with PAH; however, early diagnosis and advances in therapy increase these patients' life
expectancy. Some may succumb to their underlying disease condition rather than PAH.
According to Lau et al. (2017), 27-42% of patients with PAH have associated systemic
hypertension, 30-38 % suffer from obesity, 14% have type 2 diabetes mellitus, and 10-12% have
ischemic heart disease.
Patients with PAH may present with signs and symptoms that are non-specific and may
include clinical findings related to a patient's underlying or associated illness. The most common
symptoms are dyspnea, fatigue, chest pain, peripheral edema, near syncope, syncope, and
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palpitations (Kingman, 2020).
Diagnosis and Treatment of Pulmonary Arterial Hypertension
Diagnosis is a multi-step process that includes patient history, physical exam, diagnostic
testing, and lab findings to determine PH classification. Providers classify the disease's severity,
patient's prognosis and make treatment and management decisions using the same diagnostic and
therapeutic assessment with functional evaluation (Klinger et al., 2019). Since PAH is a
progressive disease, early diagnosis and treatment are crucial and, unfortunately, too often
delayed in 85% of patients (Maron & Galiè, 2017). This delay occurs because providers attribute
the signs and symptoms to comorbid conditions, other diseases, age-related changes, and
deconditioning (Ruben & Hopkins, 2019). According to Mandras et al. (2016), a delay in
diagnosis also occurs because of a gap in physician education and patients' lack of access to PAH
specialty centers.
Treatment goals are to slow the disease progression, improve functional class, reduce
hospitalizations, and enhance life quality (Thenappan et al., 2018). Patients with pulmonary
arterial hypertension, particularly those with Functional Class III or IV symptoms, may have
frequent hospitalizations (Tonelli, 2020). Fifty-three percent of patients with a new PAH
diagnosis experienced at least one hospitalization in the first year. About half of the admissions
are due to PAH-related congestive heart failure, indwelling line infections from catheters
delivering PAH medication, surgical placement or removal of the infusion line, and escalation of
therapy (Tonelli, 2020). Treating and managing patients is as complex as the disease itself and
requires assessment and reassessment of disease progression and treatment effectiveness. The
European Society of Cardiology ([ESC] 2015) recommends that providers assess patients every 3
to 6 months, within one month of the initiation of therapy, and any time the patient reports
worsening symptoms. They also recommend that patients be referred to and treated by a
multidisciplinary team at a center specializing in pulmonary hypertension (Galiè et al., 2016).
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Burden of Disease
There is a significant physical, emotional, psychosocial, and socioeconomic burden for
patients with any chronic illness, their families, and their caregivers (FDA, 2014). Patients with
PAH may experience the stress of a rare chronic disease with a poor prognosis. Many PAH
patients live with undiagnosed symptoms that become progressively worse and affect their
quality of life (Lau et al., 2019). Though positive, advancements in treatments have led to an
older PAH population who experience more debility and other chronic health conditions (Lau et
al., 2019). Medical management and adherence may also be challenging for patients with PAH
and requires a high degree of self-care management ability. In 2014 the US Food and Drug
Administration (FDA) interviewed patients with PAH and their caregivers as part of their
Patient-Focused Drug Development Initiative (FDA, 2014). Patient concerns centered around:
fears of symptoms continuing to worsen over time; dramatic life change post-PAH diagnosis;
declining health impacting both the patient and the caregiver; difficult medication decisions –
benefits versus drug side effects; and necessity of treatments that are "easy and safe" to manage
(FDA, 2014).
Because of the disease's complexity and the poor prognosis after hospitalization, PAH
patients' burden can be more pronounced as they transfer from one care setting to the next.
Housten et al. (2019) and Lattimer et al. (2016) stress the importance of viewing these patients as
high risk for readmissions and requiring multidisciplinary, multi-dimensional, expert, supportive
care.
Summary and Next Steps
Patients with PAH face considerable hurdles that affect both their prognosis and quality
of life. Physical and socioeconomic barriers, complicated treatment regimens, and inadequate
patient and provider knowledge often result in missed follow-up appointments and poor illness
management, leading to treatment gaps and unnecessary hospitalizations, and reduced overall
quality of life.
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Expanding medical research and evidence-based practice are ushering in new treatments
and management models for chronic illnesses, including PAH. Patients are living longer, and
there is a shift in focus to living better. Patients with PAH must have the ability to maintain,
monitor, and manage their disease and thus need a high degree of self-care management and selfefficacy to be successful (Kahraman et al., 2016). Providers need to seek out solutions that help
remove barriers and enhance self-efficacy. One approach to address these issues is improving the
hospital discharge process by leveraging technology for a postdischarge follow-up virtual visit
and close monitoring by the PAH nurse. During this visit, the provider and patient can work
towards increased patient self-efficacy and better health outcomes. Nurse-led follow-up calls will
reinforce strategies to help the patient manage, monitor, and maintain their health.
Problem Statement
The problem statement for this DNP quality improvement project is that patients at this
facility with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH)
are at risk for readmission within thirty days of discharge and inadequate self-management
skills.
The current practice for patients discharging from the hospital involves the inpatient
provider and nurse reviewing education, instructions, conducting medication reconciliation, and
answering patient questions. See Appendix B for the current process flowchart. The patient
ideally returns for a two-week follow-up visit in the clinic, which is the standard timeframe for a
hospital follow-up.
The pulmonary hypertension department identified the following issues with the current
process. The inpatient team possesses some knowledge of the PAH disease process and
medications; however, time constraints and unfamiliarity with the outpatient, self-care, and
symptom management process present a potential barrier to a successful transition from hospital
to home or another facility. Another problem is the patient's ability to attend the two-week inclinic follow-up appointment because of time, cost, or transportation issues. An analysis of 106
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of the highest acuity PAH patients demonstrated that 79.5% of them lived more than 25 miles
from the clinic. These gaps in care have led to medication errors and avoidable readmissions.
Purpose Statement
The purpose statement for this DNP quality improvement project is to implement a
hospital discharge follow-up virtual visit and weekly telephone follow-up by the pulmonary
hypertension nurse coordinator for patients with World Health Organization (WHO) Group 1,
pulmonary arterial hypertension (PAH) at the identified facility. The virtual visit and the nurse
follow-up calls will potentially address gaps in the hospital discharge process and improve the
patient's ability to monitor, maintain, and manage their symptoms, thereby decreasing
readmission rates. It is also projected to improve patient self-care management and patient
engagement. During the virtual visit, the provider will review the patient's medication list,
discuss the discharge information received and any unanticipated problems since discharge,
answer questions and reinforce self-care management, monitoring, and maintenance skills. The
nurse follow-up telephone calls beginning at 1-2 days postdischarge and conducted at weekly
intervals for three weeks will build on the provider visit's themes and create continuity of care,
defined as quality care delivered over time (Lattimer, 2016).
PICOT Question
In patients with WHO Group 1 Pulmonary Arterial Hypertension on therapy (P), how do
a post-hospital discharge virtual visit and scheduled telephone follow-up by the pulmonary
hypertension nurse coordinator (I) compared to current practice (C) affect readmission rates (O)
within 30 days of patient hospital discharge (T)?
Needs Assessment
Objective
The objective of this needs assessment was to identify and prioritize gaps in care for
patients with World Health Organization (WHO) Group 1, pulmonary arterial hypertension
(PAH) at this Pulmonary Hypertension Center of Comprehensive Care.
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Participants
The participants were two doctors, two PAH nurse coordinators, and the senior clinic
manager. All the participants are influencers in the care of patients with PAH, the target
population. The physicians both manage and treat patients with PAH. One physician is the
Pulmonary Hypertension Department Director, and the other is the Section Head for the
Advanced Heart Failure and Heart Transplantation Department, which includes the Pulmonary
Hypertension Department. The Section Head leads the five physicians, six advanced practice
providers, two hospitalists, and four fellows who may also care for PAH patients in the hospital.
The Clinic Manager oversees the entire department and is responsible for project approval and
allocation of resources.
Purpose of the Needs Assessment
Approximately 400 patients reside in Louisiana, Arkansas, Mississippi, and Texas who
receive care through this pulmonary hypertension program. Patients with PAH comprise a
population, both individual and unique. The PAH population has complex, chronic medical
issues with challenging treatment regimens, sometimes rapid progression, frequent
hospitalizations, and a high mortality rate (Lau et al., 2017). Over five years, 82% of PAH
patients visited the emergency department, with 58% admitted to the hospital (Stein et al., 2015).
Hospitalized PAH patients have a 20% chance of being readmitted within 30 days of discharge
(Bhattacharya et al., 2019). Data on readmission rates for PAH patients at this facility is not
available. However, by comparison, the all-cause readmission rate in 2019 was 16.9% and 24.4%
for heart failure (HF) (This data is collected and stored by the Medical Informatics Department).
Both the all-cause and HF readmission rates are higher than the national average, at 15.6% and
21.9%, respectively (AHRQ, 2019). Medical treatment involves various medications and
administration routes, often involving two or more different medicines managed by the patient
(Maron & Galiè, 2016). Effective disease management requires monitoring by a
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multidisciplinary team, ongoing patient and health team communication-patient, and prioritizing
patient self-care management skills (Galiè et al., 2016).
This assessment aimed to identify gaps in care and areas of improvement that, if
addressed, may improve disease management and health outcomes for this population.
Data Collection
The needs assessment was conducted at the operations meeting for the PAH department
on February 10, 2020. In addition to discussing the goals for the coming year and creating a list
of items to address ranked by importance, the participants answered questions about improving
health outcomes, safety, and quality of care for our target population. They responded to five
open-ended questions about the target population, the current process, process weaknesses and
strengths, and potential solutions. See Appendix H for the Needs Assessment Survey.
Results
The team identified the following needs for the PAH patients: clinic access, gaps in the
hospital discharge process, readmission rates, and provider and patient education.
Five of five participants ultimately decided that the focus should be on the hospital
discharge process and care transitions. Also, three of the five participants believed that more
robust disease-specific provider education was important. All felt that process, access, and
training impacted hospitalizations and readmissions for these patients. To further support the
team's answers, two recent incidents involving medication errors on the discharge medication list
led to the need for medical interventions and one readmission in the month before this
assessment. Based on these incidents, the team determined that the priority gap to address is the
discharge process. There is interest in offering one-week, post-hospital discharge virtual visits to
address issues like self-care management, medication adherence, and safety to improve overall
health outcomes for the PAH patient population.
Aim and Objectives
This project aims to implement a one-week post-hospital discharge telemedicine visit
and scheduled telephone follow-up by the PH nurse coordinator to decrease 30-day
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readmission rates with World Health Organization (WHO) Group 1, pulmonary arterial
hypertension (PAH) at this facility by March 2021. See Appendix A for the Global Aims
Assignment. The primary objectives are:
1. Reduce readmission rates below 20% for study participants
2. Achieve 95% participation in Nurse telephone follow-up call at 1-2 days
postdischarge
3. Achieve 95% participation in a scheduled one-week postdischarge virtual visit.
4. Achieve 95% participation in 3 of 3 weekly telephone follow-up calls.
5. Achieve 85% management of fluid status by study participants
6. Achieve 95% adherence to medication regimen by study participants
7. Achieve 0% signs and symptoms of infection or admissions for indwelling central
line or subcutaneous site infections
Review of Literature
A review of the literature was completed to determine telemedicine's impact on
readmission rates and PAH patients' self-efficacy. A research librarian assisted the initial search.
A search of relevant articles between 2015 and 2020 was performed using CINAHL, MEDLINE,
Ovid, Science Direct, and Google Scholar. The investigation was limited to articles published in
the English Language unless a translation was available. Search terms included telemedicine or
telehealth, pulmonary arterial hypertension, heart failure, chronic illness, virtual visit, video
conferencing, readmissions, self-efficacy, self-care, and self-care management. There were more
than 15,000 results for telemedicine and telehealth alone in the initial search. Combining terms
such as telemedicine and pulmonary arterial hypertension yielded less than ten results. However,
expanding to include heart failure or chronic illness increased that number to greater than 200.
Search criteria utilizing virtual visits or video conferencing with telemedicine and telehealth and
readmissions resulted in approximately 50 articles. Using the same rules with heart failure and
virtual visits or video conferencing returned fewer than 15 results. Combinations of telehealth
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and telemedicine with self-care and self-management yielded about 1500 articles. Approximately
1000 titles resulted when searching for self-care and self-management, and chronic illness. That
number decreased to around 900 when the term heart failure replaced chronic disease and
became two articles using pulmonary arterial hypertension as a modifier.
The author reviewed titles and abstracts of about 85 publications. Those articles were
excluded from this review if the subjects were 18 years of age. The author analyzed 40 reports
for salient content related to the project theme, objectives, and solutions.
Pulmonary Arterial Hypertension and Heart Failure
Pulmonary arterial hypertension is a chronic, progressive disease of the small pulmonary
arteries that leads to increased vascular resistance, which ultimately progresses to heart failure
and death (Yacoub & McCleod, 2018). One retrospective cohort study determined that 64% of
PAH patients died of heart failure (Tejwani et al., 2018). Admission for heart failure is a primary
reason for hospitalization, extended length of stay, and an indicator of poor prognosis in PAH
patients (Chaturvedi et al. (2020), Tejwani et al., 2018. According to Thenappan et al. (2018),
hospitalizations have decreased, but the cost and length of stay for a PAH admission have
increased.
Both HF and PAH are characterized by clinical deterioration over time, mixed with acute
episodes that sometimes result in hospitalization. The relationship between these two diseases,
the similarities in progression and symptoms, provides an opportunity to translate evidence from
one illness to another.
Heart failure (HF) is also a chronic, progressive disease characterized by the heart's
inability to pump blood, but it is vastly more prevalent than PAH. In the U.S., the number has
increased from 5.7 million to 6.2 million adults over 20 years of age (CDC, 2020b). The total
cost of treating and managing HF patients is approximately 30 billion dollars (CDC, 2020b).
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Hospital Discharges and Readmissions
There are 35 million hospital discharges nationally each year, and these patient
transitions of care, when done poorly, have been linked to preventable and costly hospital
readmissions (Alper et al., 2020). As defined by Medicare, a "hospital readmission" is an
unplanned readmission for any cause to any hospital that occurs within 30-days of the initial
hospital admission (CMS, 2020).
Readmission rates for hospitals and the quality of patient care have been inextricably
linked since the passage of the Affordable Care Act (ACA) in 2010. The ACA was a call to
action to healthcare providers and organizations to prioritize the quality of patient care and
patient safety, improve health outcomes, lower healthcare costs, and reduce hospital
readmissions (Gai & Pachamanova, 2019). In 2012, the CMS rolled out the Hospital
Readmissions Reduction Program (HRRP) to improve care delivery quality by enhancing
communication and increasing patient and family engagement, particularly in the discharge
planning process. As additional motivation for implementing this program, the CMS tied
financial risk to the outcomes such that hospitals that fail to reduce readmission rates are
penalized (CMS, 2020c). Although reduction of all-cause readmissions remains the goal, CMS
designated six conditions to measure for this program: heart failure, chronic obstructive
pulmonary disease, pneumonia, acute myocardial infarction, coronary artery bypass graft
surgery, and elective primary total hip and or knee arthroplasty. Since the implementation of the
HRRP, there has been some reduction in readmission rates, but still, in the fiscal year 2019, 82%
of hospitals were penalized for readmissions (Wadhera et al., 2020). The focus, therefore,
remains on strategies to prevent hospital readmissions.
Hospitalizations and preventable readmissions drive healthcare costs. The Agency for
Healthcare Research and Quality (2019) found this to be true in 2016 when readmission costs
outpaced the index hospitalization for two-thirds of the admitting diagnoses. Researchers
analyzed the data from 119 VA acute care hospitals and determined that the expected average
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savings for avoiding hospital readmissions was $2140 (Carey & Stefos, 2016). They also noted
that high-risk illnesses such as acute myocardial infarction, heart failure, and pneumonia carried
significantly high readmission costs.
Pulmonary Arterial Hypertension is a rare disease but still contributes to costly
admissions and readmissions. According to Bhattacharya et al. (2019), the mean charge for a
primary PAH admission was $75,980, and the readmission average was $85,842. A study
conducted by Chatterjee et al. (2017) found that the median length of stay (LOS) was five days
for the index hospitalization and seven days for the readmission. The average charge for the
index admission was $70,083 and $67,917 for the readmission.
But what is preventable readmission versus unavoidable readmission? There are several
factors identified as contributory to readmissions, which make defining preventable readmission
more difficult. Some readmissions are not avoidable due to the disease's progression,
readmissions for comorbid conditions, or other issues unrelated to the index hospitalization.
According to Uitvlugt et al. (2020), there is an average of 8.7 factors that affect preventable
readmissions, mainly related to care coordination and follow-up. Alper et al. (2020) lists early
discharge, insufficient follow-up, medication errors, inadequate discharge education, inadequate
support, failed handoffs, post-procedure complications, and nosocomial infections as driving
forces for readmissions. Uitvlugt et al. (2020) expanded on medication-related factors by
conducting a study on patients' perceptions versus providers on readmission reasons. They
concluded that patients identify medication-related factors as the cause of readmission (21% of
readmissions and 58% preventable) more than providers (15% readmissions and 23%
preventable. According to Albert et al. (2015), contributing to readmissions are "patient
characteristics and unmet needs." Patients have psychosocial, sociocultural, and physiological
traits that may present challenges to a successful transition from hospital to home or other
settings. These characteristics are frequently found in patients with heart failure and chronic
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disease, a group of patients that have statistically, had the highest rate of hospital readmissions
(Albert et al., 2015; Goldgrab et al., 2019; Jayakody et al., 2020).
Interventions
In 2018, Kash and colleagues conducted a systematic review of interventions and a
comparative study that ranked readmission reduction strategies. They selected twelve
interventions from ninety articles and assigned a percentage based on the impact on hospital
readmissions. The list included collaboration, home visits, telephone follow-up, education,
medication reconciliation, discharge planning, follow-up appointment, telemonitoring,
rehabilitation, guideline implementation, medical device, and an inpatient hospital management
unit. Based on their research, home visits, patient education, telephone follow-up, and discharge
planning significantly reduced hospital readmissions (Kash et al., 2020). They also confirmed
that collaboration and emphasis on patient accountability factored into lower readmission rates.
Albert et al. (2015) reviewed the literature on postdischarge programs and intervention
outcomes for heart failure. They found the most common interventions were patient education,
early postdischarge follow-up, self-management, telephone follow-up, weight monitoring,
sodium restriction or dietary advice, recommended exercise, medication review, and social and
psychological support. All of the programs reviewed used combinations of interventions to
optimize discharge transitions and decrease adverse events and preventable readmissions. The
research outcomes included readmissions, postdischarge emergency department visits, adherence
to follow-up visits, medication adherence, patient satisfaction, self-management skills, patient
quality of life, and health perceptions (Albert et al., 2015). The authors' research analysis
indicated that case management program models centered around early postdischarge
interventions and monitoring decreased early and late hospital readmissions. Programs that used
specialty nurses demonstrated better outcomes for heart failure patients.
In recent years, telehealth interventions have enhanced overall patient care and played a
significant role in the management of chronic disease management, demonstrating improvement
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in mortality, quality of life, patient satisfaction, reducing hospitalizations and readmissions,
increasing care access, and decreasing healthcare cost (Almathami et al., 2020; Knox et al.,
2017; Totten et al., 2020; Ware et al., 2020).
Telemedicine and Telehealth Overview
Telemedicine and telehealth are often used interchangeably (Tuckson, 2017). Generally,
telehealth is an umbrella term for utilizing telecommunication and electronic data exchange
systems to deliver healthcare between patients in one location to a healthcare team member in
another site (CMS, 2020d). Delivery services include video conferencing, patient portals,
telephones, and remote monitoring equipment that store data for later retrieval or transmit patient
data in real-time to the healthcare team (CMS, 2020d). Telehealth encompasses a broad category
of services that can be performed by any health team member regardless of certification or
degree. On the other hand, telemedicine is more narrowly the practice of medicine between a
licensed provider and patient over distance (American Academy of Family Physicians (AAFP),
2020).
Based on a survey conducted by the American Hospital Association (AHA), 76% of
hospitals utilize some modality of telemedicine, and 62% are using remote patient monitoring
(AHA, 2019). According to the American Medical Association (2018), 15% of physicians used
telemedicine for diagnosis and treatment, follow-up visits, and chronic illnesses management.
Video conferencing, also known as a virtual visit, was the most often used telemedicine
modality.
In 2016, the Agency for Healthcare Research and Quality (AHRQ) published the results
of an extensive exploration of a collection of systematic reviews to provide a selection of
evidence-based research to illuminate the potential impact of a telemedicine healthcare delivery
system. They researched over one thousand studies from 2005 through 2015 and evaluated the
evidence from 58 systematic reviews that met the inclusion criteria (Totten et al., 2016). The
authors sorted the data by clinical focus, disease state, telehealth modality, and function. The
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evidence review showed that communication, counseling via telemedicine, and remote patient
monitoring consistently demonstrated potential benefits to health quality of life, clinical
outcomes, and decreasing hospital admissions (Totten et al., 2016).
Telemedicine, in the four years since the AHRQ review, has continued to expand but
slowly. Many agencies, associations, and organizations agree that it can increase access to care,
particularly for the most vulnerable, reduce healthcare costs, and improve health outcomes.
Tuckson et al. (2017) state that telemedicine may optimize healthcare delivery by positively
impacting the "quadruple aim of healthcare," which focuses on improving the health of the
population and the patient experience, reducing costs, and increasing provider satisfaction.
The benefits of telemedicine interventions are balanced out by barriers to
implementation, like ensuring information security and privacy, insurance coverage,
reimbursement, regulations, and licensing (CDC, 2019). There are also patient-specific barriers
to consider, such as having access to the internet and technology, the ability to use the
technology, and overall willingness to accept telemedicine into their healthcare plan (Tuckson et
al., 2017). These barriers and the fact that more research is needed have slowed the pace of
widespread adoption of telemedicine (Tuckson et al., 2017). The pace has picked up significantly
since the beginning of 2020, however.
Telemedicine in a Pandemic
COVID-19, caused by SARS-CoV-2, became a global and national health crisis in early
2020 and catapulted telemedicine to the frontlines of healthcare delivery. This highly contagious
virus necessitates extreme measures to decrease the risk of exposure among the high-risk
population, the vulnerable healthcare workers, and the entire healthcare system (CDC, 2020).
Currently, there is no cure or vaccine. The best way to avoid contracting the virus is through
preventative measures such as wearing a mask, social distancing, frequent hand-washing,
cleaning and disinfecting surfaces, and monitoring symptoms (CDC, 2020). Federal and state
governments have imposed stay-at-home orders of varying degrees and recommended that all
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who can stay home do stay home. Healthcare institutions operating in crisis mode have to help
those hospitalized with the virus and those hospitalized with other illnesses while maintaining
their health and trying to keep at-risk patients with chronic diseases out of the hospital.
This shift requires a multi-faceted approach to include innovations and accelerating the
broadening of existing programs. One of those programs is telemedicine as an alternative to inperson care (Gorodeski et al., 2020).
Federal, State, and Private Insurer Response to the Pandemic
The government has expanded telehealth services to meet the need during the pandemic.
They actively encourage healthcare facilities and providers to use telehealth to safely care for
patients by encouraging social distancing (CDC, 2020). Per the CDC, changes to the healthcare
delivery system are necessary to limit health care staff exposure to the virus, reduce the risk of
shortages of personal protective equipment and mitigate the impact of too many patients
straining the system. The benefits of using telemedicine presented by the CDC (2020) are listed
in Table 1.
Table 1
Centers for Disease Control and Prevention Telehealth Benefits
Benefits
Screen patients for COVID-19 and refer
Provide low-risk urgent care
Access primary care providers and specialists, including mental and behavioral health,
for chronic health conditions and medication management
Provide coaching and support for patients managing chronic health conditions,
Participate in outpatient rehabilitation
Monitor clinical signs of certain chronic medical conditions (e.g., blood pressure, blood
glucose, other remote assessments)
Utilize case management for patients who have difficulty accessing care
Follow up with patients after hospitalization
Deliver advance care planning and counseling to patients and caregivers to document
preferences
Provide non-emergent care to residents in long-term care facilities
Provide education and training for health care providers that are not locally available,
particularly in rural areas
Note: This table lists the benefits of telehealth. From "Benefits and Potential Uses of Telehealth"
by the Centers for Disease Control and Prevention," 2020,
(https://www.cdc.gov/coronavirus/2019-ncov/hcp/telehealth.html)
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The Department of Health and Human (HHS) and CMS are instituting regulations and
policies to facilitate care delivery through telehealth (HHS, 2020). All health care providers
covered by HIPAA may use remote communication technology to deliver services to patients in
various settings and domains. These services include ambulatory and ER visits, consults,
wellness visits, follow-up visits, home health, and therapy (HHS, 2020). Likewise, patients have
greater access to these services, and CMS has relaxed enrollment restrictions for Medicare,
Medicaid, and CHIP programs (CMS, 2020d). HHS (2020) also allows providers to reduce the
fee for telehealth services and, in some cases, waive this fee altogether.
Each state governs its telehealth policy for Medicaid and many of the private insurers.
They make decisions about provider licensing, reimbursement, patient consent, and online
prescribing. During the pandemic, most states have eased licensing for providers to deliver
healthcare services across state lines (Weigel et al., 2020). Also, some states have relaxed the
rules governing prescriptions and in-person visits so that providers may prescribe to patients
based on a virtual visit (Weigel et al., 2020). Additionally, states have temporarily changed the
rule requiring written patient consent to verbal patient consent to treat. For private insurers, more
states than before the pandemic offer reimbursement for a virtual visit equal to an in-person visit
(Weigel et al., 2020).
Several medical organizations, including the American Association of Nurse
Practitioners® (AANP), the American Medical Association (AMA), and the American Hospital
Association (AHA) (AANP, 2020, AMA, 2020, AHA, 2020), endorsed the federal response to
expanding telehealth services. Recently, the Heart Failure Society of America published a report
on benefits and barriers to the implementation of virtual visits during the COVID-19 pandemic.
They noted that the virtual visit platform had increased access to care for patients, provided more
opportunities for the caregiver to be involved, and added a potential layer of privacy. Patients in
the comfort of their own homes may be more inclined to open up to providers about their health
(Gorodeski et al., 2020). For providers, the virtual visit offered a method for safely managing
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their patient's complex health conditions during a pandemic and, in some cases, strengthen the
trust bond between patient and provider (Gorodeski et al., 2020). Additionally, the HFSA states
that virtual visits allow for the reallocation of services in the time of COVID-19, continuity of
care, continued service reimbursement contributing to the financial health of the hospitals and
national healthcare system, and provide a platform for expanded telemedicine research
(Gorodeski et al., 2020).
However, with a critical need and widespread support, it is prudent to remember that
these changes are temporary, and telemedicine may look different post-pandemic. Bashshur et al.
(2020) believe it is imperative to demonstrate that safe, quality care can be delivered via
telemedicine at the same level as in-person care and is sustainable in a post-pandemic world.
Virtual Visits and Chronic Illness
According to the CDC, six in ten adults have a chronic illness, and four in ten have two
or more chronic conditions (2020). Six chronic diseases: heart disease, stroke, chronic lower
respiratory diseases, cancer, Alzheimer's, and diabetes made the top ten leading causes of death
in 2017 in the US (CDC, 2017). Overall, chronic conditions make up the bulk of healthcare costs
in the United States, accounting for 90% of the 3.5 trillion dollars in US healthcare costs
annually (CDC, 2020e). Pulmonary arterial hypertension is one of those chronic diseases with an
average estimated price of $53,000-$76,000 for the index admission and $62,000 - $85,000 for
30-day readmissions (Bhattacharya et al., 2019).
Telemedicine interventions can positively influence chronic disease management for both
the patient and the healthcare provider (Bashshur et al., 2014; Emerson et al., 2016; Gorodeski et
al., 2020; Noel et al., 2018; Ware et al., 2020). The US Government Accountability Office
(GAO) surveyed several patient and provider associations and found that patients believe
telemedicine would improve or maintain their current quality of care, particularly for those with
chronic conditions. Providers felt that different telemedicine components could improve clinical
outcomes and support treatments for chronic illnesses by utilizing virtual visits and remote
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monitoring equipment (GAO, 2017). The Community Preventative Services Task Force
(CPSTF) found that the effect of telemedicine interventions on several chronic illnesses was
better medication adherence, improved clinical outcomes, and better dietary choices (CDC,
2020). Totten et al. (2016) found that people with chronic diseases benefitted the most from
telehealth services. From the same study of the services offered, the most common telemedicine
modality is video-conferencing or the virtual visit, and the most common setting was at home.
Telephone Follow-up
Telephone follow-up is used as a singular intervention but most often is mixed with other
interventions. Telephone follow-up is also not a novel healthcare tool. It has been used by
various healthcare team members to provide patient support and education, teaches and
reinforces self-care management skills, and assists clinicians in recognizing changes in medical
status (Albert et al., 2015). A prospective study conducted by Greysen et al. (2017) showed that,
often, patients who had high levels of perceived engagement and satisfaction at discharge still
encountered unanticipated problems for which they needed assistance to correct. According to
AHRQ (2020), the phone call facilitates identifying patient questions or misunderstandings
concerning postdischarge care and addresses new problems or unanticipated health events.
AHRQ incorporates telephone follow-up in their discharge toolkit (ReEngineered Discharge
Toolkit (RED) designed to reduce hospital readmissions, provide continuity of care, and improve
patient and family satisfaction (AHRQ, 2020). Kash et al. (2018) determined that telephone
follow-up was a top-five strategy used by programs that successfully reduced readmission rates.
In a systematic review of care transitions and interventions, the most successful heart failure
discharge programs used mixed interventions that included a telephone follow-up component
(Albert et al., 2015). Odeh et al. (2019) implemented a postdischarge pharmacist-led telephone
follow-up single intervention study at a small hospital in Ireland. Results indicated a significant
reduction in 30 and 90-day readmission rates for the group who received the telephone
intervention.
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Lattimer et al. (2016) formed a workgroup that studied care transitions specifically for
PAH patients. This population described in this paper has unique challenges requiring significant
patient education and support for self-care management, particularly when transitioning from one
setting to the next. They face barriers at the care delivery level, provider level, and patient level.
Lattimer and colleagues recommend interventions that enhance transition and continuity of care,
such as a PAH nurse coordinator contacting patients within the first few days of discharge and
ongoing reinforcement of the plan of care, medication review, and symptom management.
Theoretical Framework
The key to a successful evidence-based project is selecting a theoretical framework that
provides the most appropriate lens to view one's topic systematically and thoroughly. Theories
are ordered based on their level of ideas and purpose, and there are four identified levels:
metatheory, grand theory, middle-range theory, and micro theory. The level of theory for this
project is the middle-range theory. Middle-range theories balance abstract and concrete concepts,
making them more generalizable and easily tested (Moran et al., 2017). The nursing profession
has utilized these theories to guide both evidence-based practice and research (Liehr & Smith,
2016).
The Middle-Range Theory of Self Care of Chronic Illness integrated with Symptom
Theory is the framework for this improvement project. Self-care is a process of maintaining one's
health along the life span by engaging in health maintenance and health management behaviors
during wellness or illness (Riegel et al., 2019). Chronic illness or disease is defined as a
condition that lasts longer than one year, is often activity limiting, and requires ongoing care
(Centers for Disease Control and Prevention [CDC], 2019). In chronic illness, self-care is about
managing one's condition daily to control symptoms and improve survival and quality of life.
Compared to patients with poor self-care skills, those with better self-care management
experience lower mortality rates, fewer hospitalizations, and improved quality of life (Riegel et
al., 2019).
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The concepts contained within the middle-range theory combined with self-care are selfcare maintenance, monitoring, and management. Maintenance is engaging in behaviors to help
maintain health; monitoring is noting and recognizing signs and symptoms; management is the
person's response to those signs and symptoms (Riegel et al., 2019). Symptoms affect behavior,
precisely self-care behavior. They are subjective perceptions of physical and mental changes that
occur to the individual; therefore, the interpretation of what is happening resides wholly with the
patient (Riegel et al., 2019). Patients with a chronic disease engaging in self-care react to
symptoms based on their self-knowledge, previous experiences, and what they have been taught
and understand. Symptoms theories explain how the individual identifies and responds to the
symptoms of their disease. Riegel et al. (2019) determined that the overlap amongst self-care,
chronic illness, and symptom management is significant enough to integrate the concepts into
one theory. Symptoms influence self-care in a feedback loop process of positive and negative
forces that may or may not motivate them to change their behavior, as shown in Figure 1. See
Figure 1
Self-Care of Chronic Illness

Note: From "Integrating Symptoms Into the Middle-Range Theory of Self-Care of Chronic
Illness" by Barbra Riegel, Tiny Jaarsma, Christopher Lee and Anna Stromberg, 2019, Advances
in Nursing Science 42 (3), p. 212 (doi: 10.1097/ANS.0000000000000237). Copyright 2019 by
The Authors.
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Putting Theory In Practice
For the PAH population living with a chronic illness, healthcare professionals and
patients often describe the type of self-care they need as the "new normal" (Bowling & Miklois,
2015). The "new normal" includes frequent medical appointments, tests, new medications, diet
and exercise adjustments, activity regulation, mental health maintenance, and symptom
management. Symptoms of PAH may manifest as part of the progression of the disease,
medication side effects, disruptions in medication regimen, and a lack of lifestyle modifications.
Patients may also experience hospitalizations, both planned and unplanned, becoming part of the
self-care and symptom management cycle (Tonelli, 2020).
As an example, the PAH patient monitors their weight daily and notices a three-pound
weight gain overnight. The provider has instructed the patient to take an extra diuretic the day
this occurs and call the office if they do not shed the weight or continue to gain. However, the
patient is traveling to a family crawfish boil and does not want to spend the whole day in the
bathroom, so they decide not to take the extra diuretic. The next day they are up an additional
three pounds and are short of breath. The patient now takes an additional diuretic due to
experiencing symptoms, but two days later, the patient has a ten-pound weight gain, shortness of
breath, and increased oxygen needs. The provider admits them to the hospital for IV diuresis,
which is successful, and the patient discharges home two days later.
This scenario offers an opportunity to integrate the self-care theory of illness and
symptom theory by making adjustments that treat the patient holistically. Riegel et al. (2019)
describe this as acknowledging the impact of symptoms on self-care and self-care on the
individual's symptoms. Based on the information gleaned from the patient, they need more
education on self-care management, such as taking medication as directed and recognizing and
acting to minimize dietary salt and fluid intake to decrease fluid retention. The provider may also
need to adjust the patient's medicines if fluid retention is frequently occurring. Upon discharge,
the provider may increase the patient's home dose of diuretics, discuss the importance of

28
medication adherence, and give a booklet on managing sodium and fluid intake. These actions
reflect the provider's recognition of the impact the patient's behavior has on their symptoms and
the symptoms have on the patient's behavior (Riegel et al., 2017). See Appendix D for the DNP
Project Concept Map that integrates the Middle-Range Theory of Self Care of Chronic Illness
and Symptom Theory.
Summary
The integrated theory presented here applies to the PAH population, which requires a
high degree of self-care, self-efficacy, and symptom management skills to navigate the course of
chronic illness. The provider and healthcare team can use this framework at all patient
touchpoints, including early post-hospital discharge virtual visits and telephone follow-ups.
During the virtual visit, the patient and provider will discuss the changes made at discharge,
make additional adjustments as needed, reinforce patient education, answer patient questions,
and promote self-efficacy and self-care management. 'The visit allows the patient and provider to
continue a collaborative interaction focused on supporting the patient with their mental and
physical self-care, which will improve self-care management and clinical outcomes (AHRQ),
2016). The subsequent telephone follow-up will continue the two-way communication, provide
opportunities to reinforce self-care management skills and symptom monitoring.
Methodology
Project Description
The PAH telehealth quality improvement project was developed to reduce preventable
readmissions, medication errors and promote self-care management by combining early
discharge follow-up via one-week postdischarge virtual visits and weekly follow-up telephone
calls to deliver best practice healthcare.
This health facility is in a unique position to implement this project. The PH department
is a designated Pulmonary Hypertension Comprehensive Care Center. The designation means the
department has expertise in pulmonary hypertension and has a better opportunity to deliver

29
positive health outcomes for PAH patients (Pulmonary Hypertension Association, 2020). This
project also aligns with the health systems mission to "Serve, Heal, Lead, Educate and Innovate"
in healthcare delivery.
Additionally, a commitment to technology and innovation has resulted in an
infrastructure to deliver care virtually in all modalities. At the end of 2019, this health System
had completed more than 2,100 virtual visits for urgent care and behavioral health services and
enrolled 11,500 patients in these programs. More than 9,000 patients were enrolled in the Digital
Medicine program for hypertension and diabetes, helping patients manage their chronic
conditions from home while staying connected to their healthcare team.
Project Design
Quality improvement projects prioritize interventions and practice improvement to drive
change (Moran, Burson & Conrad, 2017). The "Model For Improvement" and "PDSA" cycle
offer a framework and a method for planning and testing this change (Institute for Healthcare
Improvement, 2020). The Model For Improvement" is designed to accelerate change. The key
questions to be answered are: What are we trying to accomplish? How will we know if a change
is an improvement? What change can we make that will result in improvement? The answers to
these questions are found in the project aim, measures, and interventions.
The Plan Do Study Act (PDSA) cycle was employed to test the interventions and monitor
progress. PDSA stands for Plan, Do, Study, Act and "consists of planning the change (Plan),
carrying out the change (Do), observing and analyzing the results of the change (Study) and then
deciding what additional changes should be made (Act)" (US Department of Veterans Affairs,
2017). The PDSA Cycle methodology guided planning, implementation, and evaluation of the
implementation of telehealth supported delivery system.
This project's primary goal is to reduce 30-day readmission rates for patients with PAH
by enhancing inpatient to home transitions with a one-week, postdischarge virtual visit and
scheduled nurse follow-up telephone calls. The secondary objectives are to achieve a high
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percentage of completed virtual follow-up appointments and improve patients' ability to manage
their disease by adherence to prescribed medication regimen, recognizing signs and symptoms of
disease exacerbations, controlling fluid status, and eliminating line or site infection. The
Principal Investigator (PI) collected data on each participant through the electronic medical
record and patient interviews. The PDSA cycles tested the implementation of the two primary
interventions; the virtual visit and the nurse follow-up phone calls. Data on participant outcomes,
such as 30-day readmissions, medication adherence, and fluid management, were collected into a
secure database and visually displayed for future statistical research.
The research interventions did not have a detrimental effect on patient care. The patients
had more contact with the provider and healthcare team than the currently used standard of care.
Setting
This program will be implemented in the Pulmonary Hypertension Department within a
large nonprofit, academic healthcare system in Louisiana. The department is located at the main
facility in New Orleans, Louisiana, a Magnet-recognized, 767-bed acute care hospital. The
multidisciplinary healthcare team provides services for hospitalized patients and follows up in
our outpatient pulmonary hypertension clinic.
Study Population
This study's population was adult patients diagnosed with WHO Group 1 PAH and
managed by the multidisciplinary team at the pulmonary hypertension comprehensive care
center. The estimated enrollment was ten patients for the study period.
Inclusion criteria included patients hospitalized during the study period, who had been
diagnosed with PAH, and those newly diagnosed. Study members were required to have an
active patient portal and an iOS® or Android™ device with a MyChart application and a stable
internet or data connection. Recruitment was not limited geographically, but the location does
determine which provider conducts the visit since medical licensure is state-dependent. Disabled
patients that required a home caregiver were not excluded from this study since the designated
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caregiver may be present with the patient during the virtual visit and scheduled phone calls with
proper consent.
To qualify as a hospital readmission, the participant had to meet CMS criteria, described
as unplanned readmission within 30 days of discharge from the initial admission. Unplanned
readmissions include readmission to the same hospital or another applicable acute care hospital
for any reason (CMS, 2020c). Participants admitted to the hospital but then returned for a
planned admission were not counted as a readmission.
Exclusion criteria included patients who declined to participate in the virtual visit, did not
have the technology to connect, were discharged to a facility other than home, transitioned to
home hospice, or died during hospitalization. Patients discharged home but opting out of the
virtual visit were scheduled for the standard in-clinic visit within two weeks of discharge and
followed by the PAH nurse coordinator at variable intervals.
Subject Recruitment
The PI used purposive sampling to intentionally select patients who fit the study. The
Pulmonary Hypertension (PH) nurse coordinator was notified when a PAH patient was
hospitalized. Notification of admission happened via EMR, provider-to-provider communication,
or patient or family report. Once a patient was hospitalized, the PI followed the patient's progress
via communication with the inpatient team, attending multidisciplinary rounds, and chart review.
These methods were used to determine the patient's appropriateness, the timing of the patient's
introduction to the improvement project, and discharge planning. The severity and progression of
illness and disposition at discharge were factors in recruitment. Participants also needed access to
an iOS® or Android™ device with cellular service or Wifi connection to participate in the
virtual visit intervention arm.
Consent Procedures
The PH coordinator will inform the patient of the option for a one-week virtual visit and
scheduled nurse follow-up phone calls following hospital discharge and explain the patient's role
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in the process. If the patient verbally agreed to the postdischarge follow-up and all technical
requirements are met, the patient was asked to sign a consent form to participate in the study. See
Appendix J for the Study Consent Form. There was also a separate consent form for the virtual
visit. This form was automatically sent to the patient when scheduled for an appointment. See
Appendix K for the Virtual Visit Consent Forms.
Study Measures
Conceptual Definitions. Telemedicine is the practice of medicine between a licensed
provider and patient over distance (American Academy of Family Physicians (AAFP), 2020).
Telehealth is an umbrella term for utilizing telecommunication and electronic data exchange
systems to deliver healthcare between patients in one location to a healthcare team member in
another site (CMS, 2020d). A virtual visit is a secure audio and or video appointment between
the patient and provider via a smartphone or tablet per project facility. Telephone follow-up is a
call placed from PH nurse to PH patient following hospital discharge at scheduled intervals.
Operational Definitions. The operational definition of "hospital readmission" is defined
as unplanned readmission to the same hospital as the initial admission that occurs within 30-days
of discharge (CMS, 2020c). This facility describes a virtual visit as a secure two-way audio and
video appointment between a provider and patient. The provider uses a device with the EMR
application access, and the patient uses a personal smartphone or tablet.
Outcome Measures. There were seven expected and measurable outcomes for this
program; reduce readmission rates below 20% for PAH patients; Achieve 95% participation in
PH Nurse telephone follow-up call at 1-2 days postdischarge; 95% of PAH patients complete
their scheduled one-week postdischarge virtual visit; 95% completion of 3/3 weekly telephone
follow-up calls; 85% of PAH patients manage fluid status; 95% adherence to
medication regimen; and achieve 0% signs and symptoms, or 0% admissions for indwelling
line infections for 30-days. Evaluation and collection tools included data collection through the
Electronic Medical Record (EMR) and patient interviews conducted by the PH Nurse
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Coordinator. The existing EMR has data storage and retrieval mechanisms, including report
generation capabilities, though somewhat limited for this population. A spreadsheet was used to
track any information not covered by the EMR reports. Readmission rates were assessed biweekly. The participant interview data from the telephone follow-ups were documented in the
EMR using the telephone nurse script and evaluated weekly. See Appendix K for the Nurse
Telephone Script.
Process Measures: Process is one of the tools for evaluating healthcare, according to
Donebedian, and reflects the therapeutic relationship between patient and provider (Hickey &
Brosnan, 2017). Process measures use patient-provider interactions to determine healthcare
quality. For this project, selected criteria included the percentage of providers who conducted
postdischarge virtual visits and the number of patients moving through the protocol's steps. The
specific measurements that determined an effective process are that 80% of providers agreed to
implement the virtual visit intervention, and 85% of eligible patients participated in the new
protocol. The process measure for the scheduled nurse telephone follow-up was that 95% of
study participants completed the initial phone call and 95% completion of subsequent phone
calls. The PI observed and monitored the process measures weekly using PDSA cycles.
Balancing Measures. Balancing measures are in place to ensure that this project does
not create gaps or issues where there are none and recognizes the unintended positive impact of
the project. Safety is measured by documenting any increase in the number of readmissions
during the study above 20%. A record was also kept on provider availability and patient access
to an appointment within one week of discharge. The number of "no shows" was observed
during the study period as well.
Benefits and Risks
Benefits to the one-week postdischarge virtual visit included the opportunity for early
assessment of the patient's self-care management skills, medication regimen, disease-state
knowledge, and mental health since hospital discharge. Post-hospitalization, this earlier
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touchpoint between provider and patient allows for education reinforcement, additional learning,
and encouragement that may increase the patient's self-efficacy and self-care and moderate
preventable factors related to illness exacerbation and readmissions.
Another benefit was maintaining continuity of care by reducing barriers such as access,
time, and cost. The virtual visit also offered a safe option to patients during the pandemic. This
country is currently experiencing a pandemic, and a mitigating strategy is to maintain physical
distance to decrease the risk of exposure and spread (CDC, 2020). Remote access to healthcare
helps to overcome this barrier. Though it was not encountered during this study period, there is a
significant risk of environment-related disasters in this area. Louisiana is one of the most floodprone states in the country (Louisiana's Strategic Adaptations for Future Environments
(LaSAFE), 2019). According to LaSAFE (2019), sixty-four parishes have experienced a major
disaster over the last fifteen years due to a named tropical storm. The entire state is at an
increased risk for flooding from heavy rain, ocean surge, and river breach.
Risks for the virtual visit provider may include technical difficulties, inability to complete
some physical exam components, and feeling disconnected from the patient. There may also be
licensing and regulatory barriers (CDC, 2020). The patient may experience technical issues, have
difficulty understanding (hearing, seeing), may not feel comfortable with the "virtual"
environment, may become frustrated with the process, or have privacy issues if they do not have
space to be alone (CDC, 2020).
Subject Costs and Compensation
The only cost to the patient was for the virtual visit. At this time, the charge for an
uninsured established patient is $65.60. If the patient is insured, the insurance provider will be
billed, and the cost of the visit will depend on their coverage. The patient will receive no
compensation for participating in this project. Providers code the virtual visit as if they are faceto-face with the patient; however, the service will change based on the physical exam level
completed remotely.
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Resources and Economic Consideration
There was no cost to the facility for the implementation of this DNP project. This facility
and clinic are currently utilizing virtual visits in the outpatient setting for this population. The
cost for an uninsured established patient virtual visit is an estimated $65.60. The cost for an
insured patient is insurance dependent and determined at the time of the visit. All devices,
functionality, and environmental space exist and operate in the same manner as described in this
project. Since this is an enhancement to usual care for this patient population, the staff is in
place, and there is no need for additional resources. Also, the PI has access to database software
and computers at no cost.
Implementation
Study Interventions
The primary intervention included a one-week postdischarge virtual visit for patients that
the provider conducted. The technology, protocol, policy, coding, billing, documentation, and
consents were already in place for this visit. The virtual visit was completed one week after
discharge.
The secondary intervention was a postdischarge telephone follow-up call made by the
Pulmonary Hypertension Nurse Coordinator. The calls began 1-2 days postdischarge and then
occurred one week after the initial virtual visit for three consecutive weeks. The nurse
documented these calls in the EMR using the PAH Nurse Coordinator Weekly Telephone
Follow-up Script. See Appendix K for the PAH Nurse Coordinator Weekly Telephone Followup Script.
Pre-Implementation Phase
During this phase, meetings were held with all stakeholders to review the project goals,
outcomes, measures, and timeline. The PI completed the database template used to collect results
and informed the providers and medical assistants of the new option for a one-week
postdischarge virtual visit. See Appendix G for the Data Collection Sheets. Because of the time
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between the approval process and implementation and personnel changes within the department,
additional meetings were held after approval to review the study protocol. These meetings
included a new interim PH director, provider, clinic lead, and medical assistant who were
educated on the study. Baseline demographics, diagnoses, and treatment plans for patients
currently followed at the PAH comprehensive center are housed in the EMR.
There is no PAH patient admission data for comparison at this facility, but there are plans
to collect this data in the future.
Implementation Phase
As the implementation unfolded, the first patient was enrolled in the study on February 1,
2021. Implementation involved providers, nurses, medical assistants, schedulers, and social
workers as part of the multidisciplinary team that works with this population. The first
participant passed through all phases of the protocol but was the only patient enrolled during the
study period. There were two other potential participants, but they did not meet the criteria for
this study. The following sections highlight timeline challenges, process deviations, adjustments,
and team dynamics.
Participant Identification.
During this phase, the PI was alerted to a patient admission through direct provider
communication. The enrolled participant had a recent diagnosis of WHO Group 1 Pulmonary
Arterial Hypertension but had not started medical therapy. Once the patient had been identified
as meeting criteria on the index admission, the PI monitored the patient's progress while
hospitalized by daily chart reviews, communicating with the inpatient team, and attending daily
multidisciplinary discharge rounds. The PI recognized that the patient was too ill upon admission
to introduce the study. Once the patient was stable, the PI met with the patient and their spouse
(patient consented to have spouse present) to discuss the study protocol, and they were receptive.
It was determined through the PDSA cycle that waiting until the patient was more physically
stable offered a better opportunity for improved communication and education.
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Two participants were identified as potential PAH patients but were excluded. One
participant was transitioned to hospice during the study period, and another was referred for
advanced heart-lung transplant options.
Education and Consent.
The PI educated the patient and spouse on the protocol, reviewed the consent form, and
obtained a signature to proceed. The PI reinforced that the patient could select a follow-up
appointment in the clinic instead of the virtual visit at any time. The PI ensured the patient was
activated in the patient portal and the application was installed on their device. A virtual visit one
week from the date of discharge was scheduled. The virtual visit consent form and instructions
were automatically sent to the patient when the appointment was scheduled. The patient tested
their technology before the visit and completed consent forms. The participant did not complete
the optional survey associated with the virtual visit.
Scheduled Nurse Follow-up Call at 1-2 Days.
On day two postdischarge, the PH Nurse Coordinator contacted the patient for follow-up.
During the telehealth phone call, the nurse obtained vital signs (BP, HR, Weight, O2 Saturation),
reviewed the patient's medications, completed a symptom and functional assessment, discussed
goals, reviewed the treatment plan, answered all questions, and confirmed upcoming
appointments. While reviewing the medication list, the PH nurse coordinator noted that the
patient had not been prescribed potassium at discharge but was on a moderate dose of diuretic.
Not prescribing potassium represented a potential safety concern for the patient since diuretic use
may precipitate a hypokalemic state (Mount, 2021). The coordinator contacted the provider, who
called in a prescription for potassium. Information was documented in the electronic medical
record. See Figure 4 for the nurse follow-up workflow. As displayed, the process begins when
the patient is discharged from the hospital and the first call is scheduled. The follow-up process
repeats itself. Each call is conducted at scheduled intervals and documented in the EMR.
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Virtual Visit.
On the day of the virtual visit, the patient failed to check in at the appointment time.
Because of good team communication and dynamics, the provider and medical assistant made
minor adjustments to see other patients while the PH nurse contacted the patient. The patient was
unsure of how to sign on through the portal since they relied on their spouse, who was not home.
Their adult son was there to help with pre-check, however. The provider and the PI/PH nurse
coordinator conducted the virtual visit. The provider confirmed the patient's current dose of her
infusing medication, and the patient showed the pump to the provider. The provider also
visualized the patient's catheter site to confirm no outward signs of infection at the catheter
insertion site. It was noted that the dressing was clean, dry, and intact. There were no connection
errors during the visit. After the visit, the provider followed the standard of care to conclude an
appointment, drop charges, and document the visit.
Upon reviewing the process, PI discovered that the medical assistants do not always call
patients before their virtual visit to assist with logging onto the system. For future iterations of
this protocol, the PI will reinforce instructions for virtual visit check-in and offer to call the
patient 15 minutes before the appointment.
Scheduled Nurse Follow-up Calls.
After the one-week virtual visit, the coordinator called the participant weekly for three
weeks and followed the same telephone script. During the first weekly call, they complained of
pain and tingling to their feet, a common adverse event associated with the prostacyclin infusion.
The provider was notified and adjusted the participant's pain medication. The participant denied
weight gain greater than three pounds in 24 hours and five pounds in one week and infection
symptoms. The following week, during the coordinator follow-up call, the participant endorsed
some swelling to both lower extremities and feeling fatigued. They did not meet the criteria for
an overnight gain of three pounds or five pounds in one week. However, the provider adjusted
the participant's diuretics for symptom management. These phone calls were documented in the
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EMR.
A review of the documentation process illuminated the need for modification to the
phone call documentation. The PH nurse coordinator should use the original nurse script for the
follow-up call at 1-2 days, but a more succinct interview and documentation will be more
efficient for the subsequent phone calls.
Post-Implementation Phase
An Excel spreadsheet was used to track information not covered by the EMR reports.
Data collected in the EMR was transferred into the Excel database after de-identification, as
shown in Appendix G. The PI was challenged by only one enrolled participant during the
implementation period instead of the expected ten or more participants. Because of patient
hospitalization variability, patient course of illness, patient disposition at discharge, and
discharge date, it was challenging to capture a more robust sample during the shortened
implementation period. One participant does not allow for statistical meaningfulness, and the
choice was made to focus on the process and its feasibility for this population. This information
was shared with all stakeholders, the DNP preceptor, and the DNP committee chairs.
Process Comparison
A comparison between the pre-intervention postdischarge process to the post-intervention
process was completed. The current workflow has “unknowns” related to patient education and
medication reconciliation: The provider and inpatient nurse may have educated the patient. The
patient may have understood their disease, and the patient may have been discharged with an
accurate medication list. Before implementing the new process, the patient was solely
responsible for reaching out to the healthcare team with any questions or concerns if they
thought of them before their in-clinic appointment at around two weeks. After implementation,
the nurse was tasked with scheduled calls to contact the patient for follow-up on education, selfcare management, and any medication questions. The provider and patient could also speak
directly through the virtual visit a week sooner than the usual standard of care. Implementation
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of the new protocol for just one participant resulted in finding a medication error, providing
symptom relief, and reinforcing disease and medication education.
Figure 2 shows the existing hospital discharge process and clinic follow-up, and Figures
3 and 4 display the new process with the virtual visit option and the nurse follow-up call
workflow. The nurse follow-up process begins when the patient is discharged from the hospital,
and the first call is scheduled. The process repeats itself. Each call is conducted at scheduled
intervals and documented in the EMR. The Process Charts are also shown in Appendix B.
Figure 2
Existing Hospital Discharge and Clinic Follow-up
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Figure 3
New Virtual Visit Process Flowchart

Figure 4
New Scheduled Nurse Follow-Up Phone Call Process Flowchart
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Project Timeline
The DNP project took place between October 2020 through March 31, 2021. Preparation
began in October 2020, and project implementation started in February 2021. The original date
for implementation was scheduled to begin November 1, 2020. However, there was a significant
delay in obtaining approval from both the university and the facility. The end date was set for
March 31, 2021. On February 1, 2021, all patients meeting study criteria who consented to
participate in the study were scheduled for the postdischarge virtual visit and the four nurse
follow-up phone calls. April 1, 2021, marked the beginning of the post-implementation phase.
Data will be analyzed and disseminated to the Pulmonary Hypertension Department and the
doctoral committee representing the University of Arkansas Eleanor Mann School of Nursing.
See Appendix E for the Gantt chart depicting the original DNP project timeline and the actual
timeline.
Evaluation Plan
Data Maintenance and Security
The principal investigator used the secure hospital electronic medical record (EMR) and
an excel spreadsheet to collect data for this project. During the Pre-Implementation phase, a
patient list, which identifies those with WHO Group 1, PAH, currently treated by this PH center,
was created in the EMR. Within this list, columns displayed automatically retrieved data that
includes patient name, portal status, admission date, 30-day readmission, chief complaint, and
length of stay. The data in the list was refreshed every five minutes and manually refreshed, if
necessary. The PI exported the list from the EMR to an excel spreadsheet and added columns
that capture the project's objectives, as shown in Appendix G.
The Pulmonary Hypertension Nurse Coordinator collected data during each phone
interview on medication adherence, fluid management, and infection signs and symptoms.
Additional demographic information was collected on each patient admitted to the hospital
during the study period and recorded in the excel database.
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The PI attended multidisciplinary discharge rounds to discuss hospitalized study
participants. It was essential to attend rounds and communicate with the inpatient team to know
when patients would be discharged and discuss any social service needs. Chart reviews were
conducted weekly to track the number of patients meeting criteria or readmitted during the 30day readmission window. The PI also observed the virtual visit check-in process for the patients
100% of the time and participated in every nurse follow-up call.
Once all data was collected in the EMR, identifying information was removed,
transferred, and incorporated into the excel spreadsheet. All data was stored on the principal
investigator's (PI) secure workstation at the facility and the PI's password-protected laptop.
All data collected during the patient-provider virtual visit was covered within the virtual
visit's privacy and security rules and was entered into the secure EMR. Due to the COVID-19
emergency, the current HIPAA rules, set forth by the Office of Civil Rights (OCR) and amended
by the Health Information Technology for Economic and Clinic Health (HITECH) Act, allow
providers to use non-public facing audiovisual, remote device to communicate with patients
(HHS, 2020). Providers may use a personal device such as a phone and applications like an EMR
designed for operating systems and smart devices.
According to the Department of Health and Human Services (HHS), providers can use
applications such as "Apple FaceTime, Facebook Messenger video chat, Google Hangouts video,
Zoom, or Skype" to provide telehealth services to their patients (HHS, 2020). At this facility,
providers may use either an iPad® or iPhone® with the EMR application. All virtual visits are
completed within the EMR, and patient consent is embedded in the workflow. If the patient can
only conduct an audio visit, the consent form must be read aloud before completing the visit and
documentation.
Data Analysis
The primary outcome measured was the effect of a one-week postdischarge virtual visit
and weekly telephone follow-up on readmission rates. In the first week of implementation, the PI
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was able to enroll one participant, and that participant was able to complete all phases of the
quality improvement project. Unfortunately, subject recruitment was limited by participant
characteristics and time. The project aims to capture patients transitioning from the hospital to
home and reducing 30-say readmission rates. Therefore, recruitment relies on the patient being
hospitalized and discharged, then followed for 30 days postdischarge. The final project timeline
spanned approximately two months. The project should run for a minimum of six months with an
ideal time of one year to increase sample size and provide usable quantitative data.
Because of the shortened implementation timeframe and lack of participants, data was
not collected on ten patients as initially planned in this proposal. Statistical analysis was not
possible for a sample size of one. However, process feasibility was studied. One participant
completed each step of the process and was not admitted to the hospital within 30-days of
discharge. It was determined that it is possible to implement a protocol that follows PAH patients
after discharge in a systematic fashion and yield positive results.
Outcome Measures
There were five expected and measurable outcomes for this protocol.
Outcome #1: Reduce readmission rates below 20% for study participants
Nationally, hospitalized PAH patients have a 20% chance of being readmitted to
the hospital within 30-days of discharge (Bhattacharya et al., 2019). Data is not available
for this population at this time; however, the rate for system-wide, all-cause hospital
readmissions in 2019 was 16.9%, and specifically for heart failure, it was 24.4%. This
outcome was measured using the EMR and patient or provider reports. See Figure 1 for a
visual representation of the readmission rate for the participant enrolled in this study.
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Figure 5
Readmission Rate
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The final three outcomes were assessed during the nurse telephone calls.
Outcome #2: Achieve 85% Management of Fluid Status by Study
Participants
Fluid status is recorded by nurse interview and patient report of weight during
each call. Weight gain of 3lb overnight or 5lb weight gain in one week indicates that the
patient may be "volume up" and need medication adjustments or hospitalization if other
criteria are met, such as shortness of breath and increased oxygen needs. The participant
reported some swelling and fluctuations in weight, but they did not meet the criteria.
Reported weights were 177 => 181 => 175 => 179 => 183. The provider made
medication adjustments for symptom relief, and the patient did not have to be admitted to
the hospital.
Outcome #3: Achieve 95% Adherence to Medication Regimen by Study
Participants
Adherence to medication regimen was measured by nurse interview and patient
report. The patient reported taking their medication as directed. Of note, the patient has a
continuous infusion that is self-managed and titrated as tolerated. The medication comes
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with specialty pharmacy support and education, including a home visit and telephone
calls, but this is only in the initial stages of beginning the medication.
Figure 6
Outcomes 2 & 3

Achieved Percentage
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Outcome #4: Achieve 0% Signs and Symptoms of Infection or Admissions
for Indwelling Central Line or Subcutaneous Site Infections
This outcome is measured by nurse interviews, patient reports, and images
uploaded by the patient if available. Not all PAH patients will have a central line or
subcutaneous administration site. However, the enrolled participant did have a central
line and site, and the dressing remained clean, dry, and intact. The patient did not report
any signs and symptoms of infections such as fever, redness, warmth, drainage, or pain at
the site.
Process Measures
Process measures help determine the effectiveness and efficacy of an
improvement project. PDSA cycles were used to observe and monitor the implementation
process to facilitate the project, note any barriers, and make adjustments. See Appendix F
for the PDSA Cycles. Other selected process criteria included the percentage of providers
who conducted postdischarge virtual visits and the number of patients moving through
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the protocol's steps. The specific measurements that determined an effective process are
that 80% of providers agreed to implement the virtual visit intervention, and 85% of
eligible patients participated in the new protocol. The process measure for the scheduled
nurse telephone follow-up was that 95% of study participants completed the initial phone
call and 95% completion of subsequent phone calls. Only one patient enrolled during this
study period, but they did complete all phases of the protocol. One provider was
scheduled to see this patient for the one-week virtual visit, and that visit was completed.
The chart in Figure 7 shows the process measures with target and actual percentages.
Should this QI project be restarted, this chart will be used.
Process Measure #1: Achieve 95% Participation in PH Nurse Telephone
Follow-Up Call At 1-2 Days Postdischarge
This outcome was measured by the nurse interview and documented in the EMR.
The one participant was called on the second day postdischarge and completed the
telephone interview. As stated in the implementation section, a medication error was
discovered based on the call's information. According to Housten et al. (2019), structured
patient follow-up by the nurse is a "simple, cost-effective method of assessing patient
status and wellbeing, reviewing key discharge education and instructions, and identifying
issues that may lead to poor outcomes."
Process Measure #2: Achieve 95% Participation in a Scheduled One-Week
Postdischarge Virtual Visit
The participant completed the virtual visit with the provider at the one-week
postdischarge mark. This outcome was measured using data from the clinic schedule
within the EMR. Early clinic follow-up offers an opportunity to review discharge
instructions, reinforce education, and address any unexpected problems faced by the
patient in the outpatient setting (Housten et al., (2019), Lattimer et al. (2016)).
Process Measure #3: Achieve 95% Participation in 3 Of 3 Weekly Telephone
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Follow-Up Calls
The nurse completed 3 of 3 weekly telephone calls to the participant. The length
of the call varied depending upon their input. Some of the data was not always available
because the participant did not consistently measure their vitals. During these calls, the
nurse discovered that the ordered physical and occupational therapy had not been started
on this patient, resulting in a call to the home health agency to begin services. Also, the
provider adjusted the patient's fluid medications and PH infusion based on another call.
Additionally, the nurse reinforced the need for the patient to take their vitals once
a day and weigh themselves daily. By week three, the participant had created a daily
diary that contained their vital signs and weight. The goal is to add a symptoms diary as
well.
Figure 7
Process Measures
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Process Measures
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

1-2 Day Phone
Call

Virtual Visit

Weekly Phone
Call 1

Weekly Phone
Call 2

Weekly Phone
Call 3

Actual

100%

100%

100%

100%

100%

Target

95%

95%

95%

95%

95%

Balancing Measures
Balancing measures are in place to ensure that this project does not create gaps or issues
where there are none and recognizes the unintended positive impact of the project. Safety is
measured by documenting any increase in the number of readmissions during the study above
20%. A record was also kept on provider availability and patient access to an appointment
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within one week of discharge. Of note, the provider pool decreased from 6 providers to four
during this study period. The number of "no shows" was observed during the study period, and
there were none. The patient experience is vital to any patient-centered intervention. The
participant had the opportunity to fill out a survey regarding the virtual visit embedded in the
workflow.
Discussion
Healthcare Quality and Safety
Implementing a virtual visit during the pandemic is tied directly to safety as it reduces the
risk of exposure to the patient and healthcare workers (HHS, 2020). Beyond the pandemic
environment, the patient and provider's ability to connect one week after discharge instead of 2
weeks or more can affect patient safety by providing an early opportunity for education and
reinforcement of self-care management skills. Additionally, telephone follow-ups completed by
PAH Nurse Coordinators improved patient clinical outcomes and self-care management skills.
Though there was only one patient enrolled in this protocol, they completed all phases and
avoided rehospitalization within the 30-day window. The nurse's first call to the patient resulted
in the discovery of a medication error. The subsequent three calls resulted in medication
adjustments by the provider, order clarification, and patient symptom management education.
Chronically ill patients benefit from effectively managing their disease, positively impacting
their quality of life (Riegel et al., 2019). The patient with a better comprehension of their health
will reduce the risk of adverse health events such as medication errors and improve patient safety
(AHRQ, 2019). With this knowledge, the healthcare team can work with the patient to build
upon the existing information to increase self-care management, self-efficacy, and health
autonomy. (Stewart, 2020).
The findings mirror those of an extensive systematic review published by AHRQ. The
results from 58 systematic reviews demonstrated that patient quality of life and clinical outcomes
were improved by communication between the healthcare team and the patient, counseling via
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telemedicine, and remote patient monitoring. These interventions also decreased hospital
admissions (Totten et al., 2016). Jayokody et al. (2018) researched the effect of 48-hour
telephone follow-up on 18,659 chronically ill participants. They determined that a reduction in
emergency department visits and at least one adverse event in 28 days was associated with
implementing the telephone protocol.
Economic and Cost Benefits
This quality improvement project did not yield enough subjects to adequately assess the
health care system's impact by reducing hospital readmissions for PH patients and the overall
hospitalized population. The lone participant did remain out of the hospital for greater than 30
days. Hospitalization for PAH patients can be an economic burden for all involved. On average,
their hospitalization costs more than that of a heart failure patient (Highland et al., 2019). The
PAH population is almost exclusively admitted to telemetry beds and often ICU beds, with an
average daily cost of $2,700 at this facility. In a retrospective study, Bhattacharya et al. (2019)
found that the mean cost for admission was $75,980, and the mean for readmission was $85,842.
The virtual visit and the nurse coordinator follow-up calls may have been a factor in the
participant not being rehospitalized since the provider made adjustments that relieved symptoms,
and the nurse reinforced patient self-care management. The promotion of self-care management
skills, particularly for patients with chronic illness, has been shown to reduce overall
hospitalizations, whether implemented as a singular intervention or in conjunction with other
interventions (Horwitz & Krumnholtz, 2020). The virtual visit may also decrease access barriers
such as transportation and cost for the patient and result in fewer "no shows" or rescheduled
appointments. The participant and their caregiver avoided a 2.5-hour drive back to the clinic
using the virtual visit option. The participant's caregiver stated that it was a hardship to make the
drive because of money and time, and they appreciated the chance to speak with the provider so
soon after discharge.
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Limitations
Factors that have affected the project's results included time, sample size, participant
characteristics, the lack of comparative statistics, and personnel. This study's original timeline
was for a minimum of three months, but the actual timeline was one month. The implementation
timeframe severely limited participant enrollment and the protocol's implementation since it
spans the 30-day period following hospital discharge. Participants had to be admitted during the
study period and meet the criteria to be selected for this protocol. Therefore the PI was not able
to recruit patients or rely on a selected sample population. Also, the course of illness for each
patient is different and affects how long they are in the hospital and disposition at discharge. For
the future, this study's ideal timeframe would be six months to a year, which should increase the
sample size. Also, participants will have more time to begin the 30 days and complete the
protocol.
Another limitation was the lack of comparative statistics for the PAH population at this
facility. To address this limitation, the PI used National statistics for readmission rates for PAH
patients and included the facility all-cause admission rates and the heart failure admission rates.
Additionally, key stakeholders and resources left the organization during the life of this
study. Fortunately, the new interim PAH department directed was familiar with the project and
stepped into the role quickly. The other loss was one of two PAH Nurse Coordinators. The PI
designed the project so that one nurse could do the bulk of it, and they were able to handle the
work due to the small sample size. There will need to be adequate staffing to execute the nurseled follow-up phone calls going forward.
Sustainability
This facility continues to use and invest in telemedicine and telehealth, so the
virtual visit should remain as part of the clinic operations. Since March of 2020, the facility has
conducted over 100,000 virtual visits to date (Ochsner Health System, 2021). The interim PAH
department director is interested in continuing this protocol for this population. All data collected
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and the final DNP project will be kept within the PH department and accessible for reference.
Recommendations
Practice Implications
The one-week postdischarge virtual visit can be used with any group of patients
discharged from the hospital. The provider can also use the virtual visit for outpatient follow-up
not associated with a hospital discharge. Telephone follow-up is usual care for this department,
but there is no standard timeframe for follow-up or a written script or documentation template.
There is an opportunity to create these tools and protocols.
Policy Implications
This project will add to the growing body of knowledge supporting sustaining and
expanding upon the relaxation of telehealth policies and regulations for federal, state, and private
insurers. Before the 2020 global pandemic, telemedicine varied by state and by the insurance
provider, and the insured's usage was low. In 2019, forty-two states had enacted some form of
telemedicine parity law for private insurers (Laktman et al., 2019). Providing coverage for
telehealth, however, did not correspond to usage by employees or enrollees. In 2019, 82% of
companies with 5,000 or more employees offered telehealth benefits, but only 2.4% of the
enrollees used them (Rae et al., 2020).
According to Weigel et al. (2020), to continue the momentum post-pandemic, health
insurers should treat telehealth services the same as in-person health services, ensure that patients
can access telehealth from their homes, allow audio-only provider-patient videos, and commit to
investing in technological infrastructure for rural areas.
At the department level, this project may lead to a change in postdischarge follow-up protocol
for the PAH population to include an earlier visit and weekly telephone calls. They may also opt
to update the standard timeframe for follow-up in the other sections.
Dissemination
Brownson et al. (2018) believe that the passage of health knowledge to the public and
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eventually to policy is negatively impacted by ineffective dissemination. Translational research,
moving it from the scientific domain to the public domain, is the "art" that pairs with
implementation science. According to White and Zaccagnini (2017), there are two dissemination
purposes; sharing with stakeholders and academia and sharing with a broader professional
audience.
Pulmonary Arterial Hypertension is a rare disease, and as such, it is even more imperative
to share data, both qualitative and quantitative. Advances in diagnoses and treatments of diseases
that are novel, affect a small population and have few subject matter experts benefit from
translational research and dissemination (Courbier et al., 2017).
Site and DNP Committee Reporting
The PI will share findings with the Pulmonary Hypertension multidisciplinary team and
stakeholders via presentation. Since the postdischarge protocol can be applied to various patient
populations, it will also be shared with the other sections in this department, such as "Heart
Failure." The project will be shared with the Pulmonary Hypertension Professional Network
through publication and presentation at the symposium. The PI will also present via audio/visual
modality and submit the project in its entirety to the University of Arkansas, Eleanor Mann
School of Nursing doctoral committee. Additionally, the project will be shared with the
Evidence-Based Nursing Research Department at this facility and presented, if accepted, as an
abstract at the facility EBP conference.
Professional Reporting
The PI may share the quality improvement project with the Pulmonary Hypertension
Professional Network (PHPN) and present it at the bi-annual PHPN conference scheduled for
Sept. 30-Oct. 2, 2021. The PHPN conference hosts nurse practitioners, nurses, pharmacists,
physicians, physician assistants, social workers, and other allied health professionals. It provides
an opportunity to share and discuss the latest advances in the field of pulmonary hypertension.
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Conclusion
There is little argument that America has a chronic disease “problem.” According to the
Centers for Disease Control (CDC), in 2012, half of all adults in the United States had one or
more chronic health conditions (2017). It is also clear that the healthcare landscape is changing
rapidly and advancing technology in all life areas.
Pulmonary hypertension is a chronic illness and a rare disease that makes patients
vulnerable in all aspects of care. It is one of those illnesses that necessitate empowering the
patient with self-care management skills and removing barriers to quality health care. The time
following hospital discharge is a particularly high-risk period for patients with PH and requires a
multidisciplinary approach delivered by a healthcare team of experts in PH (Housten et al.,
2019). If efforts are unsuccessful, the result may lead to readmissions, adverse events,
medication complications, and inadequate self-care management skills (Housten et al., 2019;
Moreo et al., 2017).
Questions surrounding how providers deliver quality care, attain access to care equity,
and the costs to all, monetarily, physically, and mentally, for any patient drive the need for a
better health care delivery system. As has been shown, chronic illness requires ongoing
collaboration between the patient and healthcare team to promote self-care management skills
(AHRQ, 2016).
One answer to these questions is to combine existing technology with quality health care
delivery to connect the patient and healthcare team. Though this QI project was limited by
sample size and time, the single participant completed the protocol, including the visit and four
nurse follow-up phone calls. During the follow-up, patient safety was addressed by finding a
medication error; access was increased, costs were mitigated, patient education was enhanced,
and the patient avoiding being readmitted to the hospital within 30 days of discharge.
Additionally, it was demonstrated that the protocol is feasible to implement.
There is a place for telemedicine interventions to reduce hospital readmissions and
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enhance chronic disease management skills. Continuing implementation of this protocol would
improve our ability to deliver safe, effective, efficient, timely, patient-centered care to improve
patient outcomes for the PAH population and other chronically ill populations.
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Appendix A: Global Aims Assignment

Write a Theme for Improvement: _Transitions of Care_________________
Global Aim Statement

Create an aim statement that will help keep your focus clear and your work productive:
We aim to improve: transitions of care for patients with World Health Organization
(WHO) Group 1, pulmonary arterial hypertension (PAH) at this facility
(Name the process)
In: the Pulmonary Hypertension Comprehensive Care Center
(Clinical location in which process is embedded)
The process begins with: identifying gaps in the current process.
(Name where the process begins)
The process ends with implementing a provider-led post-discharge follow-up virtual visit
and nurse-led telephone follow-up call process in the thirty days after hospital discharge
for patients with World Health Organization (WHO) Group 1, pulmonary arterial
hypertension (PAH) at this facility.
(Name the ending point of the process)
By working on the process, we expect: Reduce readmission rates below 20% for study
participants; achieve 95% participation in scheduled one-week postdischarge
virtual visit; achieve 85% management of fluid status by study participants; achieve 95%
adherence to medication regimen by study participants; 0% signs and symptoms or
admissions for indwelling central line or subcutaneous site infections.
(List benefits)
It is essential to work on this because improving the process will reduce readmission rates
and improve symptom and self-care management.
(List imperatives)
Create Flowchart
Specific Aim Statement
We will:  improve  increase  decrease
The:  quality of  number/amount of  30-day rehospitalization rates________
(process)
To:________less than 20%________________________________________________
(percentage)
To/By: offering a 1-week post-discharge virtual visit and nurse-led telephone follow-up call
process in the thirty days after hospital discharge ____________________________
(describe the change in the quality or state the number/amount/percentage)
By: March 2021
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Appendix B. Process Charts
Existing Hospital Discharge and Clinic Follow-up

New Virtual Visit Process Flowchart
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Appendix B. Process Charts
New Scheduled Nurse Follow-Up Phone Call Process Flowchart
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Results
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chronic
disease
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treatments

Search
terms:
'pulmonary
arterial
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artery
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' and 'PAH'
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Review cost
of PAH on
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health care
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cost of
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Gu, S., Hu,
H., & Dong,
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evidence on
economic burden
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effectiveness of
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effectiveness
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Systematic
Review

8 studies
examined
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USA and
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Strength
of
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Successful
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of
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care team.
Patients felt
that
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were
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Level I
Small
sample
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insured
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All studies
had
estimates of
annual or
monthly
direct health
care costs
per patient,
but none
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Published RCT’s,
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Comparing
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Health
Related
Quality of
Life

Meta-analysis
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participants
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receiving

Data
Collection
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Summary of
Results

Strength
of
evidence

Telemedicin
e
significantly
increased
overall
quality of life
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MetaAnalysis
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'economic',
'cost',
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'health
expenditures
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cs of each
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study
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title and
abstract of
each
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study.
SPSS (v21)
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Results
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not
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Results
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well as
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and
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days with
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patient
activation by
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Experimental
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2014
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Results
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were $75,980
and $85,842,
with SPH
totaling
$53,084 and
$62,585,
respectively.

Level V
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Authors

Year

Country

Theory
guiding
study &
ID of
Variables

Independent or
Treatment
Variable(s)

Dependent
or Outcome
Variable(s)

Design type

E., . . .
Heresi, G.
A.

Sample
(n =)
Method

Data
Collection
tools

PH registry

Stein, P. D.,
Matta, F., &
Hughes, P.
G.

2015

Levine, D.
M., Dixon,
R. F., &
Linder, J. A.

2018

USA

Slightam,
C., Gregory,
A. J., Hu, J.,
Jacobs, J.,
Gurmessa,

2020

USA

USA

Adults with
Group 1 PAH
(ICD 9 – 416.0)

Hospitalizati
ons, deaths

N/A

Virtual visit vs
usual care

BP control,
primary care
office visits,
specialist
office visits,
ED visits,
and inpatient
admissions
in the 180
days before
and 180
days after
the inperson
visit

Retrospective
cohort study
with
adjustment by
difference-indifferences

N/A

Video visits

Patient
satisfaction/
preferences

Survey

N/A

Retrospective
study

Brief
Summary of
Results

Strength
of
evidence

85% died of
RHF postdischarge
Nationwide
Emergency
Department
Sample,
2007-2011

From 20072011 the rate
of ED visits,
hospitalizatio
ns, and deaths
in patients
with Group 1
PAH
decreased

Level V

n = 1051
VV and n =
24,848in
person visits

EHR

BP control
was
equivalent
between the
groups and
decreased use
of primary
care

Level V

n = 764
respondents
who
completed
baseline and

Baseline
survey then
post visit
survey sent
3-6 mos

Significant
patient
satisfaction
with video
visit or

VI

n= 64,451
20%
stratified
sample on
hospital
characteristi
cs of US
hospitalbased Eds.
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Authors

T.,
Kimerling,
R., . . .
Zulman, D.
M

Year

Country

Theory
guiding
study &
ID of
Variables

Independent or
Treatment
Variable(s)

Dependent
or Outcome
Variable(s)

identify
primary
health care
access
barriers (2)
examine
patient
experiences
with tablets
and any
changes in
perceived
access to
care, and (3)
investigate
the patient
characteristi
cs associated
with
preferences
for video
visits vs inperson care.

Design type

Sample
(n =)
Method

follow-up
survey
n= 530
baseline
only

Data
Collection
tools

later

Brief
Summary of
Results

equivalent to
in person
visit.
Identified
patient
characteristic
that influence
preference for
video visits.
Patients less
likely to
report
preference for
video visits if
they had
more chronic
conditions.
Qualitative
analyses
identified 4
themes
related to
preferences
for videobased care:
perceived
improvement
s in access to
care,
perceived
differential
quality of
care,
feasibility of
obtaining

Strength
of
evidence
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Authors

Almathami,
H. K. Y.,
Win, K. T.,
& VlahuGjorgievska,
E.

Year

2020

Country

Australia
and
Saudi
Arabia

Theory
guiding
study &
ID of
Variables

N/A

Independent or
Treatment
Variable(s)

Dependent
or Outcome
Variable(s)

Design type

Systematic
Review

Sample
(n =)
Method

n = 45

Data
Collection
tools

Brief
Summary of
Results

Database
search Scopus,
Association
for
Computing
Machinery,
PubMed,
and Web of
Science.
Yielded
2518
articles.

necessary
care, and
technologyrelated
challenges
Identified
barriers and
facilitators to
telemedicine.
They found
some benefit
to
telemedicine
services
although
barriers still
exist for some
patients.

Strength
of
evidence

2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension – Evaluation and summary of all evidence on pulmonary arterial
hypertension; management, treatments, outcomes, recommendations for practice.
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Appendix D: Concept Map
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Appendix E: Gantt Chart

Initial Timeline
8/2/20

9/21/20

11/10/20 12/30/20

2/18/21

4/9/21

Complete and upload DNP project proposal draft and…
Receive approval of DNP project proposal from…
Present DNP proposal to committee
Obtain IRB approval from the University of Arkansas
Obtain IRB approval from the clinical site
Educate staff on use of UPP tool
Implementation - Screen, schedule, collect data
Data Analysis
Complete final presentation
Disseminate results to clinic site

Revised Timeline
8/2/20
Complete and upload DNP project proposal draft and…
Receive approval of DNP project proposal from…
Present DNP proposal to committee
Present DNP proposal to System Nurse Research Council
Obtain IRB approval from the University of Arkansas
Obtain IRB approval from the clinical site
Educate team on study protocol
Implementation - Screen, schedule, collect data
Data Analysis

Complete final presentation
Disseminate results to clinic site

9/21/20 11/10/20 12/30/20 2/18/21

4/9/21
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Appendix F: PDSA Cycles
PDSA - Patient Enrollment
OBJECTIVE: Implement protocol
Change Idea: Enroll participants in study

Plan: Monitor EMR for pulmonary hypertension patient admissions.
Enroll participants in the study
Do: Followed up with admitted patient. Educated and consented
patient for study. Patient had activated patient portal. Attended
multi-disciplinary discharge rounds and communicated with team to
remain aware of discharge date. Patient discharged to home on
2/17. Scheduled virtual follow-up for 2/26. Contacted patient at day
2 post-discharge. Used nurse script to guide interaction.
Study: Challenges to this study are the lack of control over admission
dates and discharge dates but only in the context of a set project
timeline. Once the process is approved and added to the guidelines,
the admission and discharge dates will not be a factor. Another issue
is that a patient or provider may not be available for an appointment
at exactly one-week postdischarge. There will need to be some
flexibility in the virtual visit date.
Act: Will note exactly how many days postdischarge the
appointment is scheduled to illuminate any potential issues. Will
create a qualitative question about the patient's experience to add
to the interventions. This will be provided to the University and
Facility team for review and approval. Adding this question does not
trigger a re-submission to IRB.

Person
Responsible
PRINCIPAL
INVESTIGATOR
PRINICIPAL
INVESTIGATOR

PRINCIPAL
INVESTIGATOR

PRINCIPAL
INVESTIGATOR;
Chair and head
of Facility Nurse
Research dept.

Due Date
2/1/2021Ongoing
2/8/212/19/21

2/1/2021
- life of
the study

2/18/2021
2/26/2021

PDSA Process Cycle - Provider
OBJECTIVE: Monitor Provider Participation
Change Idea: Observe and calculate a percentage of providers who conducted postdischarge virtual
visits
Person
Responsible
Due Date
Plan: Schedule study participants with different providers for virtual PRINCIPAL
2/1/2021visit.
INVESTIGATOR
Ongoing
Do: Followed up with admitted patient. Educated and consented
PRINICIPAL
2/8/21patient for study. Patient had activated patient portal. Attended
INVESTIGATOR
2/19/21
multi-disciplinary discharge rounds and communicated with team to
remain aware of discharge date. Patient discharged to home on
2/17. Scheduled virtual visit for 2/26.
Study: Challenges to this study are the lack of control over admission PRINCIPAL
2/1/2021
dates and discharge dates but only in the context of a set project
INVESTIGATOR,
- life of
timeline. Once the process is approved and added to the guidelines, Providers, PH
the study
the admission and discharge dates will not be a factor. Another issue Nurse
is that a provider may not be available for an appointment at exactly Coordinator
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one-week postdischarge. There will need to be some flexibility in the
virtual visit date.

Act: Noted that PI was able to schedule patient for the following
week as planned, however the date was not exactly one week.
Providers rotate through clinic and see outpatients regularly. Also,
provider options decreased from 6 to 4 during this study period.
There has to be a slot available for the postdischarge patient or the
visit may be pushed to later than one week.

PRINCIPAL
INVESTIGATOR,
Providers,
2/18/2021
2/26/2021

PDSA Process Cycle - Patient
OBJECTIVE: Monitor Patient Participation
Change Idea: Observe and calculate a percentage of patients who complete the visit and phone calls.
Person
Responsible
Due Date
Plan: Schedule study participants with different providers for virtual PRINCIPAL
2/1/2021visit.
INVESTIGATOR
Ongoing
Do: Followed up with admitted patient. Educated and consented
PRINCIPAL
2/8/21patient for study. Patient had activated patient portal. Attended
INVESTIGATOR,
2/19/21
multi-disciplinary discharge rounds and communicated with team to Providers, PH
remain aware of discharge date. Patient discharged to home on
Nurse
2/17. Scheduled virtual visit for 2/26. Additionally, patient
Coordinator
availability when they are home is variable. The nurse may need to
make more than one attempt to contact patient.
Study: Challenges to this study are the lack of control over admission PRINCIPAL
2/1/2021
dates and discharge dates but only in the context of a set project
INVESTIGATOR,
- life of
timeline. Once the process is approved and added to the guidelines, PH Nurse
the study
the admission and discharge dates will not be a factor. Another issue Coordinator
is that a patient may not be available for an appointment at exactly
one-week postdischarge. There will need to be some flexibility in the
virtual visit date and the phone calls. Also, the patient may contact
the nurse at any time during the weeks following discharge. The
nurse should document those calls as part of standard of care but
still complete a planned call that follows the nurse script. Of note,
the PH Nurse Coordinator team decreased from 2 nurses to 1, so
resources became a challenge.
Act: Noted that PI was able to schedule patient for the following
PRINCIPAL
week as planned, however the date was not exactly one week due to INVESTIGATOR,
provider availability. There was not a set appointment time for the
PH Nurse
follow up call so the PH nurse coordinator had to call and leave a
Coordinator,
2/18/2021
message on at least one occasion (the call was still completed).
Facility Managers
Department is searching for a new nurse to fill the vacant position.
2/26/2021
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Appendix G: Data Collection Charts
Project ID

Active Portal

A

YES

Date
1-2 day Call
Virtual Visit
Week 1
Week 2
Week

PH
Completed
Medication
Visit
1
Yes
IV Remodulin
Yes
IV Remodulin
Yes
IV Remodulin
Yes
IV Remodulin
Yes
IV Remodulin

Type of
Device
CADD Pump
PH
Medication
2
Adcirca
Adcirca
Adcirca
Adcirca
Adcirca

Admission
Date

Reason for
Admission

Overload/New
2/1/2021 Diagnosis PH
PH
Medication
3
None
None
None
None
None

Missed doses of
medications
No Rx
None
None
None
None

Discharge
Date
2/17/2021
Reported
Weights

Length of
Stay (LOS)

Readmission
Date

16
Weight Gain
3# overnight

177
181
175
179
183

0
0
0
0
0

Reason for
Readmission
0

Weight Gain 5#
in 1 week
4
-6
4
4

0
S&S of
Infection
0
0
0
0
0
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Appendix H: Needs Assessment Questionnaire

Needs Assessment Questionnaire
The purpose of this questionnaire is to gather information about the care of our pulmonary
hypertension population. The information obtained will be used to improve processes and health
outcomes for this patient population. Information collected from interviews will be confidential.
The interview should take approximately 15 minutes to complete.
Role: Administrator (1), Section Head, MD (1), PH Department Director, MD (1), PH Nurse
Coordinator (2)
Employment Status: Full time (5)
1. What is currently in process in our department?
Answers: REVEAL Calculator; inpatient IV/SC order sets, preparation for PH Director
transition; EPIC PH snapshot
2. Where is there room for improvement in our department?
Answers: PH patient discharge/transition to home or other setting – med reconciliation,
patient discharge education; outpatient clinic access; clinic process and workflow; ability
to retrieve data from EPIC for PH patients; staffing needs – nurse coordinator assistance;
provider education
2. What are the top areas to work on to improve the things that are not working
well?
Answers: outpatient clinic access, gaps in the hospital discharge process, and provider
and patient education
4.

What are some solutions?

Answers: Early discharge follow-up for PH patients, clinic access – virtual visits and
create a process/workflow and role responsibilities; education materials – meet with
patient education coordinator; discharge checklist or education packet; add staffing help
to PH department
5. What resources do we have to assist with these solutions?
Answers: Nurse Coordinators, Medication manufacturers/specialty pharmacy, patient
education coordinator, LPN/MA, Epic Team
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Appendix I: Study Consent Form
IMPLEMENTATION OF A POSTDISCHARGE VIRTUAL VISIT AND NURSE
FOLLOW-UP PROTOCOL INTERVENTION

PRINCIPAL INVESTIGATOR (PI)
Kimberly C Thompson
University of Arkansas Eleanor Mann School of Nursing
606 N. Razorback Rd.
1-504-842-0948
kcthomp@uark.edu
FACULTY ADVISOR
Dr. Thomas Kippenbrock
University of Arkansas Eleanor Mann School of Nursing
606 N. Razorback Rd.
479-575-4560
tkippen@uark.edu
PURPOSE OF PROJECT
You are being asked to take part in a graduate school project. Before you decide to participate in
this project, it is important that you understand why the project is being done and what it will
involve. Please read the following information carefully. Please ask the PI if there is anything
that is not clear, if you need more information or would like the PI to read it out loud to you.
The PI is working with the University of Arkansas, Ochsner Health System and your Ochsner
Pulmonary Hypertension team to study a new hospital follow-up plan. The plan includes a
virtual visit with your provider one week after your discharge from the hospital. It also includes a
phone call from your nurse coordinator within one to two days after discharge and three weekly
calls after your virtual visit. Previously, you would be scheduled for an in clinic visit with your
provider one to two weeks after hospital discharge. Also, your nurse coordinator will reach out to
you at more frequent intervals following your hospital discharge.
The purpose is to decrease hospital readmissions withing 30 days of discharge, increase access to
healthcare by reducing the travel, cost, and time for you. It also provides an earlier chance for
you, your provider, and your nurse to review your care instructions, your medications and to
discuss any concerns you may have about managing your condition at home.
IMPORTANT DEFINITIONS
▪
▪
▪

A virtual visit a secure audio and or video appointment between you and the provider.
The visit is scheduled and completed through your patient portal, using a smartphone or tablet.
The virtual visit will take the place of the standard one to two week in-clinic visit following your
discharge from the hospital.
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o

▪

▪

Note: You may still request an in-clinic visit with your provider at any time. You will
also continue to be scheduled for your regular follow-up appointments.
The second part of the study is that you will receive a phone call from your PH nurse one to two
days after you leave the hospital and then once a week for three weeks after your virtual visit.
o Note: You may still call or email your PH nurse at any time, Monday through Friday, 85, with any questions or concerns.
Telephone follow-up is a call placed from PH nurse to the PH patient following hospital
discharge.

PROJECT PROCEDURES
▪
▪
▪
▪
▪

You will be screened by the PI to determine eligibility for the virtual visit.
You will be scheduled for the virtual visit.
The PH coordinator will call you 1-2 days after you are discharged from the hospital
After you complete your virtual visit, the PH coordinator will call you in 1 week and
weekly for 2 more weeks.
You and your healthcare team will:
o Discuss your disease process,
o Review your medications,
o Discuss signs and symptoms to watch out for and what to report to your team.
o Discuss when to seek emergency medical care and
o Confirm follow-up appointments

RISKS
▪
▪

There are no risks associated with this study.
Potential loss of patient privacy and confidentiality of data collected during this study can
occur. The principal investigator and the facility are committed to handling all patient
data in accordance with HIPAA standards.

BENEFITS
▪ Decreased chance of being hospitalized within 30 days of discharge.
▪ Early contact with your healthcare team for post-hospitalization assessment.
▪ Reduced travel and cost associated with travel to your appointment
▪ Increased self-care management skills
CONFIDENTIALITY
▪
▪

Any information that has identifying data will be stored in your secure electronic medical
record (EMR) as it is now.
Any data collected outside of the EMR will be “de-identified” which means any
identifiers associated with you will not be used. This includes: any part of your name,
date of birth, address, or social security number.

CONTACT INFORMATION
▪

▪

If you have questions at any time about this project, or you experience adverse effects as
the result of participating in this project, you may contact the principal investigator,
whose information is provided on the first page.
If you have questions or concerns about your rights as a research participant, you may
also contact Ro Windwalker, the University's Human Subjects Compliance Coordinator,
at 479-575-2208 or send an email to irb@uark.edu.
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INFORMED CONSENT AND VOLUNTARY PARTICIPATION
What is informed consent?
▪ Informed consent is an agreement to take part in a study.
▪ It gives you facts about the study so that you can decide if you want to participate or not.
▪ The form will explain the study and the benefits and risks.
▪ You can choose whether you want to be in the study or not.
▪ If you decide not to participate it will not affect your health care.
▪ You can agree to be in the study and then change your mind later.
▪ Your PH (pulmonary hypertension) coordinator will help you with the consent form.
CONSENT
I have read, and I understand the information provided. I have had the opportunity to ask
questions. I understand that my participation is voluntary and that I am free to withdraw at any
time, without giving a reason and without cost. I understand that I will be given a copy of this
consent form. I voluntarily agree to take part in this project.

Participant's signature ______________________________ Date __________
Investigator's signature _____________________________ Date __________
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Appendix J: Virtual Visit Consent Form
Informed Consent for Virtual Visit
PURPOSE: The purpose of this form is to obtain your consent to participate in a “virtual visit” telehealth
consultation.
DESCRIPTION: What is a virtual visit? To better serve the needs of its patients, Ochsner is offering interactive
video communications between some patients and their Ochsner health care providers, when appropriate. This is
referred to also as “telehealth.” In this way, you may be evaluated and treated by your provider from a distant
location.
Since this may be different from the type of visit with which you are familiar, it is important that you understand and
agree to the following:
1. My physician will be at a different location than me for the virtual visit.
2. My physician will document the virtual visit in my Ochsner medical record.
3. I will be informed of the relationship between me and my physician or other provider treating me and the role he
or she will serve in my care.
4. I will be informed if any health care provider is to be present with me at my location to assist in the visit.
5. There are potential risks to this technology, including:
In rare cases, information transmitted may not be sufficient (e.g., poor resolution of images) to allow for
appropriate medical decision-making by the physician.
Delays in medical evaluation and treatment could occur due to deficiencies or failures of the equipment.
In very rare cases, security protocols could fail, causing a breach of privacy of personal health
information.
I or my health care provider can discontinue the virtual visit if it is felt that the technical connections are not
adequate for the situation or if I have any concerns about confidentiality or the ability of my physician to render
proper care to me in this setting.
6. I have been informed how to receive follow-up care and emergency care.
7. I have been informed how to receive care in the event of a technology or equipment failure.
8. All existing laws regarding my access to my medical information and copies of my medical records apply to this
virtual visit. I have been informed how to obtain copies of medical records and/or insure transmission, or
forwarding, to another medical provider.
9. Video, audio, and/or photo recordings may be taken of me during the procedure.
10. Reasonable and appropriate efforts have been made to eliminate any confidentiality risks associated with the
virtual visit, and all existing confidentiality protections under federal and Louisiana state law apply to information
disclosed during the virtual visit.
11. I have the option to decline to receive medical services by telehealth and may withdraw from such care at any
time without affecting the right to future care or treatment at Ochsner.
CONSENT
I have read, understand, and agree to all information set forth in this document and agree that all applicable blanks
were filled in prior to my signing. This information, including, but not limited to, the benefits and risks of this care
and alternative treatment options to telehealth, was discussed with me, in language that I understand, by my Ochsner
health care provider(s). During this discussion, my provider(s) gave me the opportunity to ask any and all questions
I had regarding the information set forth in this document and answered any such questions I had to my full
satisfaction.
I hereby agree to participate in virtual visit telehealth services, as described above, and authorize my Ochsner
physician to utilize telehealth in the course of my diagnosis and treatment. This authorization for and consent to my
participation in virtual visit telehealth services are and shall remain valid until revoked by me verbally or in writing.
________________________________ ________________________________________
Signature of Patient
Signature of Patient Representative (where required)
____________________________
_______________________________________
Signature of Witness
Patient Representative Print Name
_________________
__________________ ____________________________________
Date
Time
Relationship to Patient
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Appendix K: PAH Nurse Coordinator Weekly Telephone Follow-up Script
Discharge Date:
Primary Discharge Diagnosis:
How is the patient feeling since discharge from the hospital?
Vital Signs (If known)
BP:
HR:
O2%:
Temp:
Current Weight:
Medication Review
Discharge Medication Review:
Medication reconciliation performed? ☐ YES

☐ NO

Did the patient have any difficulty/problems filling prescriptions? ☐ YES

☐ NO

Notes:
PAH Diagnosis Specific Medication Review:
Name

Frequency

Side Effects (If Any)

Does the patient have any questions regarding medications? ☐ YES ☐ NO
Notes:
Oxygen and Order Review
Does the patient use oxygen?
☐ NO
☐ YES
☐ ATC
☐ WITH ACTIVITY
☐ AT NIGHT
Notes:

LITER FLOW ________
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Was Home Health and any equipment ordered for the patient upon discharge?
☐ YES☐ NO
Home Health
If yes, has home health contacted patient
and/or initiated services?
Name of Home Health Agency
Durable Medical Equipment (DME)
If yes, has the DME provider contacted
patient and delivered equipment?
DME Company
Pulmonary Hypertension Symptom Checker
☐ DIZZINESS
☐
☐
☐
☐
☐
☐
☐
☐

SHORTNESS OF BREATH
FEELING TIRED
FAINTING
SWOLLEN LEGS, ANKLES
SWOLLEN ABDOMEN, FEELING OF FULLNESS
COUGH
WEIGHT GAIN 3# OVERNIGHT
WEIGHT GAIN 5# IN 1 WEEK

☐ OTHER
Central Line/Site Assessment
PUMP SETTINGS:
TYPE _____________ DOSE: _____________ RATE _______________
☐ FEVER
☐ REDNESS
☐ PAIN
☐ WARMTH
☐ DISCHARGE
DESCRIBE ___________________________________________________
☐ DRESSING, C/D/I
☐ OTHER
Activity Assessment
☐
☐
☐
☐

NO SYMPTOMS
DO YOU HAVE SYMPTOMS WITH ORDINARY ACTIVITY?
DO YOU HAVE SYMPTOMS WITH MINIMAL ACTIVITY?
DO YOU HAVE SYMPTOMS DURING ACTIVITY OR REST?
Education & Flag Review

Was the patient educated on "red flags" or things to watch for? ☐ YES
If yes:

☐ NO
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"Red flags" patient was told to watch for:
✓ Struggling to breathe or unrelieved shortness of breath while at rest
✓ Experience chest pain or heart palpitations that persist
✓ Experience pre-syncope or syncope
Is the patient experiencing any red flags today? ☐ YES

☐ NO

Notes:
Education provided (Pathophysiology, Indications, Treatment, Symptom Management, Medication,
Social and Emotional Guidance, Support Resources, Other):

Patient Goals
What activities are you able to do today?
What activities would you like to be able to do?
How do you know when you are having a "good day?"
How many good days have you had in the last week?

Patient Follow Up
Phone number patient will call if having any questions or problems:
Appointment scheduled? ☐ YES

☐ NO

DATE: _____________

Follow-up/transition of care appointment, including the date/time and location of your
appointment:
Diagnostics scheduled? ☐ YES

☐ NO

Notes:
Provided patient with date, time, and location of follow-up appointment if they do not have it:
Notes:
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Appendix L: DNP Project Title Form
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Appendix M: Statement of Mutual Agreement
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Appendix N: IRB Approval - Facility
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Appendix O: IRB Approval - University of Arkansas

